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1 Azabicyclo amino acids  
 
1.1 Introduction  
 
The synthesis and the use of conformationally rigid unnatural compounds have 
attracted the chemists’ interest since long time.1, 2 It is commonly assumed that the 
restriction of the flexibility by structural modifications, such as the insertion of a 
cyclic scaffold, is an efficient tool to reduce the possible structural conformations of 
a molecule. Some examples of these rigid scaffolds are reported here below. 
 
Figure 1  
1 2 3 4 5 6
 
 
In particular non-natural amino acids containing  the rigid backbone moieties 
indicated in figure 1 are particularly interesting. With  respect to the natural 
constrained amino acids, i.e. proline, rigid amino acids are characterized by “fixed”  
bond length and torsional angles. Furthermore, cyclic amino acids (CAAs) are 
versatile molecules as they are used in a wide range of applications in different 
fields. As single molecules, they often possess biological activity and in many cases 
they are characterized by higher efficiency, stability and receptor selectivity with 
respect to the natural ones. Their features are particularly profitable, when these 
unnatural scaffolds are inserted in peptides, as they can improve the selectivity 
toward a receptor, the stability to enzymatic hydrolysis and so the bioavailability. 
Another  application field of CAAs is their use as rigid ligands in organometallic 
catalysis and also as organocatalysts into asymmetric reactions. 
In the past decades a huge numbers of constrained amino acids were synthesized. 
Since the focus of our researches were the preparation of CAAs  containing an 
azabicyclo scaffold, (see paragraph 2) in the following paragraphs are presented 
selected examples of the constrained amino acids containing an aza-ring and some of 
their applications. 
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1.2  3 and 4 member azacyclic amino acids.  
 
This class of compounds is represented by synthetic and naturally occurring products 
holding a three and four member rings3 responsible of the conformational rigidity. 
Some examples of these azacyclo compounds are reported in figure 2. 
 
Figure 2 
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Aziridine constrained amino acids 7 can be considered as fixed glycine derivatives. 
Chiral aziridinecarboxylic acids 7 are prepared through an asymmetric synthesis. 
Some examples are reported below. The key stage in these transformations is the 
Sharpless catalytic asymmetric epoxidation (Scheme 1), obtaining the intermediate 
12 than converted in few steps in the compound 14. Alternativelly an asymmetric 
aziridination of a C=C double bond was performed to give compound 16. (Scheme 2) 
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1-Azaspiro[2.2]pentane-2-carboxylic acid 20 is obtained through the reaction of 
methyl(chloro)cyclopropylideneacetato with primary amines or ammonia (Scheme 
3). 
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Four member aza-rings were initially synthesized in racemic form starting from γ-
butyrrolactone.4 Since now, there are only few efficient methods for the preparation 
of these derivatives in enantiometically pure forms. The first example is reported in 
the 2003 year. The aza-cyclo compounds 25a,b were obtained starting from amino 
alcohol 21 as shown in the scheme 4.5  
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Scheme 4 
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The development of new methods for the synthesis of these compounds was 
encouraged for their potential use both as precursors of alkaloids, β-lactam 
antibiotics and other biological active compounds as well as  constrained analogues 
of natural amino acids which are used in the synthesis of peptidomimetics.6 
 
1.3 Bi- and polycyclic conformationally rigid amino acids 
  
Amino acids discussed in the following sections represent bi- or polyclic structures, 
in which  the nitrogen atom is incorporate into the ring. Consequently, these 
compounds have  the  φ and χ
  
fixed torsion angles, inducing particular conformations 
in peptidomimetics. 
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1.3.1 Conformationally rigid bicyclic proline rings 
 
Proline 26 occupies a special place among proteinogenic amino acids due to its 
unique structure. In this amino acid, the nitrogen atom is incorporated in a five 
member ring, which gives rise of conformational changes with respect to other 
natural amino acids. These features are more pronounced for amino acids with a 
further strained ring.  
In order to confer conformational rigidity to the five member-ring, it is necessary to 
introduce a bridges with a length of 1 or 2 atoms into the molecule. When such a 
bridge links two adjacent or non adjacent positions in the ring, proline 
methanologues are formed. Examples of this classes of compounds are reported in 
Figures 3 and 4. 
Cis-3,4 propane–L-proline 27 is found in nature. Other derivatives such as amino 
acids 28-29 were prepared and tested as interesting organocatalysts and also as 
buildings blocks in peptide sequences.  
 
Figure 3 
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As example of this class, the synthesis of compound 277 is reported below (scheme 
5). The key reaction step is the cyclization of compound 33  to compound 34 than 
easily oxidized to compound 27  
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Scheme 5 
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2-Azabicyclo[2.1.1]hexane-1-carboxylic acid 36 was first isolated in 1980 from the 
seeds of legume Ateleia Herbert smithii and more recently from the plant Bocoa 
Alterna. It plays an important role in protecting the seeds from insect predation. 
 
Figure 4 
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Different synthetic methods are possible  to access to this compound taking 
advantage of a very efficient method such as the photochemical cyclization of 
compound 37 to 38, then hydrolyzed to the amino acid 36.8 (Scheme 6) 
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Scheme 6 
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Alternatively, a new method for the synthesis of the 2,4-methanoproline 36 includes 
a [2+2]-cycloaddition reaction between dichloroketene 39 and allylchloride 40 to 
give 41 then transformed into the imine 42. After reaction with 2-hydroxy-2-
methylpropanenitrile, a cyclization occurred giving 43, the precursor of amino acid 
36.9  
 
Scheme 7 
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Azabicyclo[2.2.1]heptane carboxylic derivatives contaning a five member ring are 
very interesting compounds  widely employed in the synthesis of several 
conformational rigid peptidomimetics (see sections 1.5).10  
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Despite the apparent  simplicity of the preparation of 2-azabicyclo[2.2.1]heptane-3-
caboxylic acid derivatives, there are only few known representatives of this class. 
The most utilized method is a Diels-Alder reaction of cyclopentadiene 48 and imine 
49, generated in situ. This method allowed to prepare compound 44 in gram scale.11 
 
Scheme 8 
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As reported in figure 6, it is also possible to generate a series of the above derivative 
by functionalization of the double bond of the primary cycloadduct 50.  
 
Figure 6 
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Concerning the 7-azabicyclo[2.2.1]heptane-3-carboxylic acid 46, an intramolecular 
cyclization reaction starting from functionalized cyclohexane derivatives is the useful 
approach for its preparation.12 One example is reported below.  
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Scheme 9 
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In alternative, the cycloaddition of alkyne 55, with  N-Boc pyrrole gives the adduct 
56 than converted into compound 47. 
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1.3.2 Conformationally rigid bicyclic pipecolic derivatives 
 
Pipecolic acid 57 is a non-natural cyclic α-amino acid that represents a proline 
homologue. To confer rigidity on the pipecolic acid framework, a bridge linking 
positions 2 and 5 or 3 and 6 have to be included into the ring. Some examples of 2-
aza[2.2.2]octane derivatives are reported here below. 
 
Figure 7  
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A large number of these derivatives were synthesized and successfully used for the 
preparation of  peptidomimetics and foldamers. (see section 1.5) 
 
The most useful synthetic method to access to these compounds is a Diels-Alder 
reaction between 1,3-cycloexadiene and an imine. Functionalized derivatives of this 
class can be obtained by modification of the double bond.  
 
Scheme 11 
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Aiming to confer rigidity into the proline ring, an other strategy is to insert the 
proline ring in a more complex policyclic structure (compounds 64, 65) or to 
introduce sp2-hybridised atoms into the ring as compound 63. 
 
Figure 8 
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1.4 Rigid Amino acids as drugs  
 
Different conformational constrained unnatural amino acids, were used as single 
drug molecules. The rigid scaffold oriented the pharmacophore in the space, thus 
improving  the selectivity, the bioavailability and the stability of these compounds in 
biological systems. Despite the high interest, only few examples of amino acids 
containing the aza-ring have found an application. Examples are reported in Table 1. 
 
Table 1 
Compound Name Therapeutic applications 
NH
COOH
 
66 
2,4-methanoproline Agonist for mGluR 
COOH
HN
HOOC
NH2
 
67 
2-(4-amino-4-
carboxybutyl)aziridine-2-
carboxylic acid 
Irreversible inhibitor of 
diaminopipemelic acid 
epimerase13 
HOOC COOH
HN
 
68 
2-(2-
carboxyethyl)aziridine-2-
carboxylic acid 
Irreversible inhibitor of 
glutamate racemase14 
 
Table 1. Unnatural amino acids as pharmaceutical and drug components. 
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1.5 Rigid amino acids in peptidomimetics  
 
The preparation of peptides is the most wide and extended field in which rigid AAs 
have found applications. 
The design and the use of constrained amino acids  in the preparation of 
peptidomimetics with controlled backbone folding is one of the main strategy aiming 
to preorganize a flexible peptide into a biologically active conformation responsible 
of the binding to a receptor. Preorganized molecules are expected to play a lower 
entropic cost upon complexation. As a consequence, an  improved  selectivity profile 
and bioavailability can be expected.  
In general rigid amino acids can stabilize a α-, β-, or γ-turn or a β-strand motive that 
are frequently found in the biologically active conformations. 
Since the secondary structure of peptides can be described in terms of the torsion 
angles φ, ψ and ω, and the conformation of the side chains of amino acids can be 
described in terms of the torsion angles χ1, χ2, χ3, these parameters  play a very 
important role in the conformation of a peptide fragment. Values of the torsional 
angles φ, ψ and ω in peptides and proteins containing natural amino acids, were 
determined as a result of numerous experimental structural data and computational 
simulations.  
By evaluating the values of the torsion angles of a conformationally rigid amino acid, 
it is possible in general to predict its effect on the secondary structure. 
In particular, if the rigid amino acid presents angles close to the native one, a 
stabilization in the secondary structure is expected, otherwise the destabilization and 
change in the secondary peptide structure can be predicted with sufficient accuracy.  
 
Figure 9 
 
 
 
 
 
 
Torsion angle Notation 
  
C-N-Cα-C φ 
N-Cα-C-N ψ 
N-Cα-Cβ-Cγ ω 
Cα-Cβ-Cγ-Cδ χ1 
 
C
N
H
Cα
C
H
N
Cα
O
Cα
O Cβ
Cχ
Cδ
Cε
ω
χ1
χ2
χ3
ϕ
ψ
 
Cβ-Cγ-Cδ-Cε χ2 
 19
In the ideal case, the ω0 angle is 0° for the cis-configuration of the peptide bond and 
180° for the trans-configuration. In the majority natural proteins, the peptide bonds 
have a trans-configuration although bonds with the cis-configuration are sometimes 
encountered. Furthermore, the peptide bonds of cyclic amino acids with a nitrogen 
atom in the ring, the NH-CO bonds can be non-planar since amino acids form tertiary 
amides. In fact, these residues, are characterized by noticeable pyramidalization of 
the nitrogen and carbon atoms of the bond NH-CO and by ‘twisting’ around this N-C 
bond. The following parameters have been suggested for quantitative description of 
the conformation of such a non–planar amide fragment: the twist angle τ [τ is the 
angle between the planes defined by the atoms C(1)NC(2) and OC(3)C(4); 
parameters ω0(N) and ω0(C) which reflect pyramidalization of a bond at the nitrogen 
and carbon atoms, respectively; the tilt angle δ is formed between the N-C(3) bond 
and the plane defined by the C(1)C(2)N atoms. A strong pyramidalisation of nitrogen 
atom bonds and ‘twisting’ of the amide bond can be achieved in a rigid system, such 
as derivatives of 1-azaadamantan-2-one 69. 
 
Figure 10 
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                     [τ = δ = 0°, ω0(N) = 360°]                  [τ = 90° δ = 57°, ω0(N) = 326°]             
 
Here below are reported some examples of peptidomimetics containing the amino 
acids mentioned in paragraph 1.1 and 1.2 and the above parameters will be discussed 
for the peptide fragments bearing these rigid moieties. 
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1.5.1 Conformational rigid cyclic and spirocyclic amino acids with 3 and 4 member 
rings.  
 
Aziridine amino acids are characterized by strictly fixed φ and χ angles. Since small 
peptides containing this scaffold present an high toxicity, due to the high reactivity of 
aziridine ring toward nucleophyles, their use as drugs is very limited. 
 
Figure 11 
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Nevertheless, conformational properties of such peptides may be judged from the 
single-crystal X-ray diffraction studies of compounds 74 and 75 from which is 
evinced a significant pyramidalization of the nitrogen atom. This is evidently a 
consequence of  the angle strain in the three-member ring. The δ distortion angle in 
those dipeptides, is about 37-38°, this mean that the nitrogen atom is virtually 
tetrahedral as in the case sp3-C hybridisation. 
 
Figure 12 
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Compounds holding a spiro[2.2]pentane skeleton, were characterized by strongly 
distorted bond lengths and angles. In particular the C-C bond of the spiro atom is 
0.07 Ǻ shorter and the angles are strongly distorted (in range of 59 to 134° of 
distortion angles δ). 
Compound 10 is enough stable to permit the preparation of a short peptide sequence. 
In order to study the secondary structure induced, it was incorporated into the novel 
simple peptide structure 76. 
 
Figure 13  
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Many natural compounds, such as the mugineic acid 7715 or the nicotinamide 7816, 
that contain the azetadine-2-carboxylic acids 8 in their structure, have been reported. 
 
Figure 14 
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The four member ring in compound 8 is conformationally flexible but it acquires 
conformational rigidity when is inserted in a peptide sequence because the nitrogen 
atom is involved in the amide bond.17 Further studies confirm that this ring is virtual 
planar. For this reason, these amino acids were often incorporated into synthetic 
peptidomimetic new drugs. 
As examples, pharmacologically important molecules such as the thrombin inhibitor  
Melagatran 79 or Exanta 8018, are hire reported which have been prepared from 
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compound 8 by modification of the known thrombin inhibitor, viz., Boc-D-Phe-Pro-
Arg-H 81. 
 
Figure 15 
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The replacing of Pro by their conformationally contrained analogous Aze  in this 
tripeptide resulted in a two fold increase in the inhibitory activity.  
 
Figure 16  
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1.5.2 Proline derivatives  
 
Rigid proline analogues 27, 28 and 29 may be considered analogues of valine, 
leucine, and glutamic acids respectively.  
Compound 27 is strongly constrained  and was successfully employed in the design 
of mimetics of polyproline II helix. It  plays also an important role in the process of 
intracellular signal trasmission.  
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Figure 17 
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A detailed conformational computational analysis of di- and tripeptides containing  
residue 27 or compounds 28 or 29 shown that the torsion angles φ, ψ, χ1 and χ2 are –
70°, 131°, -57°, and –158°. These values agree with angles typical of the  polyproline 
II helix.  
 
2,4-Methanoprolines (2,4-MePro) 35 and 36 are naturally occurring proline 
analogues. Their bond lengths are close to those of proline but the angles are in some 
cases different as reported in Table 2. 
 
Table 2 
 
Value (deg) Angle 
2,4-MePro         
(compounds 66) 
Proline 
 
N-C(5’)-C(4’) 97.0 103 
C(3’)-C(4’)-C(5’) 103.1 103 
C(3’)-C(4’)-C(6) 100.5 103 
C(2’)-C(3’)-C(4’) 82.4 103 
C(2’)-C(6)-C(4’) 81.9  
 
Small peptides containing a 2,4-MePro residue (compounds 83-86) are characterized 
by fixed torsion angles φ and χ. The distortion of these two angles is generated by the 
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deformation of the framework. Some examples of these compounds have been 
deeply investigated by NMR spectroscopy and X-ray diffraction.19 
    
Figure 18 
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1.5.3 Azabicyclo[2.2.1]heptane derivatives 
 
Azabicyclo[2.2.1]heptane derivates were widely employed in the synthesis of 
different conformationally rigid substances. In particular, aza-derivates of 
norbornane were used in the design of rigid amino acids proline analogues.  
The analysis of the bond length and the angles of structure 44 reveled that they are 
virtually identical to those in proline except for the pyramidalization at the nitrogen 
atom (δ = 14° and τ = 8°). However the corresponding peptide bonds are non-planar. 
The non-planarity of the amide bonds is evidenced by the values of angles 
(compound 87, ω0 = 358°). 
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Figure 19 
87
N
O
O
 
 
For the sake of structural elucidation, two model oligopeptides containing residue 46 
(for this residue, a notation Ahc is adopted) has been synthesized. According to the 
X-ray diffraction data, the angle φ in the protected dipeptides 88 and 89 are strongly 
deviated from the theoretical value of 0°. 
 
Figure 20 
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1.5.4 Pipecolic and analogue Bicyclo[2.2.2]octane derivatives 
 
Compound 58 is quite often used as an analogue of proline although it is actually an 
analogue of pipecolic acid and no substantial difference in the bond angles is 
observed. X-ray diffraction analysis indicates that the C-C bonds are slightly longer 
(0.03 Å) than those of  pipecolic acid. Instead, no substantial difference in the bond 
angles were observed. 
Amino acids containing a bicyclo[2.2.2]octane framework are widely studied 
considering the huge number of compounds containing this scaffold. An analysis of 
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the structural data indicates that amino acids with this framework are characterized 
by distorted torsion angles especially in the case bulky substituted compounds. 
Theoretically, the value of the φ angle in derivates of 2-azabicyclo[2.2.2]octane-3-
carboxylic acid, assumed the symmetrical framework and the undistorted amide 
bond, is –60°. According to X-ray diffraction data, this value is – 65° for compound 
91. In Zabicipril 90, the respective torsion angle is –63°. The pyramidalization 
parameter (ω0) of the nitrogen atom in 92 is 359.7°. Distortion of the amide bond is 
also insignificant (τ = 4° and δ = 9°), i.e., the amide bond in derivatives of 2-aza-
bicyclo[2.2.2]octane is virtually planar.  
According to X-ray diffraction data, the amide bond is characterized by the trans-
configuration (ω = -172° and  ω = -174° for 92 and 90, respectively). 
 
Figure 21 
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1.6 Rigid amino acids in organocatalysis  
 
Organocatalysis represents one of the most active research field in the last decade. A 
range of catalysts of varying structural complexity were developed. An 
organocatalyst is “an organic compound of relatively low molecular number and a 
simple structure capable of promoting a given trasformation in substoichiometric 
quantities”.20 Organic catalysts offer several advantages with respect to the 
traditional transitional metal mediate reactions. Organocatalysts are generally 
cheaper because in many cases are naturally derived compounds. They can often 
easily handle under wet and aerobic conditions, and there are not associated to toxic 
problems. However in some cases in order to have good performance the catalytic 
loading is too high. 
Examples of organocatalysts were reported first in 1960’s in which natural organic 
compounds such as alkaloids (chinchona) or natural amino acids (proline) were used 
as the catalyst in asymmetric reactions. Aiming to developed better catalysts, amino 
acids, and in  particular the constrained ones, have found a central role and also 
interesting applications. 
The most readily available catalytic systems within this field are undoubtedly the 
proteinogenic α-amino acids, with proline derivatives arguably the most commonly 
used as organocatalysts.  
The first pioneering example of an amino acid used as catalyst, was the asymmetric 
Robinson annulation reported in the early 1970s. A catalytic amount of (S)-proline 
was enough to mediate the aldolcyclization of compound 93 in 100 % yield and 93 % 
ee.21 The polar aprotic DMF was found to give the shorter reaction time and the 
highest enantioselectivity and yield.  
 
Scheme 12 
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Advantages on the use of proline are that it is cheap, very powerful and easily 
available in enantiomerically pure form. For these reasons it is the most utilized 
organocatalyst. Nevertheless  some examples were reported  in which the catalyst is a 
fixed proline derivatives that performs similar or better results with respect to 
proline. 
Here below are reported some examples of  rigid proline derivatives used as 
organocatalysts.22  
 
Scheme 13 
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The goal in the use of the rigid proline catalyst is that the loading is much lower 
compared to the native proline. 
Also aldol reaction was studied using rigid proline derivatives reported in table 3 
which gave a good selectivity also using acyclic ketones.23 
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Table 3  
Catalyst Yield ee (%) 
HN
COOH
 
36 
99 % 87 % 
H
N
HOOC
 
46 
100 95  % 
N
H
COOH
 
44 
95% 91 % 
 
 
Even if, the used of rigid amino acids containing azaring as organocatalyst is a 
promising application field,  since now not many examples are reported in literature.  
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1.7 Rigid amino acids as metal ligands  
 
Amino acids were used as metal ligands since long time, but this research field is 
also actual for the “bioorganic applications”.24 In this sense, promising researches 
pointed out the attention on small peptide containing unnatural rigid amino acids that 
can conveniently replace a complex enzyme structure and are normally more stable 
than the native one. Very important, is the active site responsible of the catalytic 
reaction general makes up a transition metal, coordinated  to a serie of amino acids.25 
An evaluation of the intrinsic binding energy ∆Eint, between the metal in the metal 
fragment  [XnM]*, and the ligand L* (these asterisks designate a simplification that 
the ligand and the fragment have the some energy in the complex  [XnML]), can be 
obtaining according to the electron transition state (ETS) scheme.26 The bonding 
energy between two fragments is described by the three interaction terms shown in 
Equation 1.27 
 
Equation 1   
∆Eint = ∆EPauli + ∆Eelsta + ∆Eorb 
The first term ∆EPauli quantifies the Pauli repulsion between the electrons on the two 
fragments. The electrostatic attraction between the two fragments is named ∆Eelsta 
and the 
 
∆Eorb represents the orbital interaction term, which quantifies the energy gain 
upon mixing the orbitals of the two fragments. Only analysing all these energy 
parameters is possible to evaluate the energy of  metal-ligand interaction. 
The ∆EPauli plays an unfavourable role  for the ligands with rather extended occupied 
pi orbitals such as C2H4, C2H2, and CO and is not counterbalanced by a strong 
electrostatic interaction ∆Eelsta. This  latter term is also especially large for NHC 
complexes in fact N atom is a σ donor but does not have an important pi retro 
donation. Furthermore N atom can also change its hardness character, depending on 
the different functional group in which is involved. As an example,  in an oxazoline, 
N atom revealed a hard character, but in an amine its character is more soft. These 
characteristics and the different orbital energy ∆Eorb make nitrogen atom one of the 
most interesting useful and versatile “bindings atom” for transition metal.  
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Natural and unnatural amino acids have been used since long time as  ligands for 
transition metal in order to create interesting chiral organometallic catalysts. 
However in literature are reported only few examples of azacyclic rigid amino used  
as transition metal ligands. 
 
In complex 103 the proline ring is condensed in a more complexes structure that 
became rigid when the iron ion Fe2+ was deeply incorporated in the amino 
structure.28 Compound 103 could be inserted in a peptidic sequence for the design of 
mimic enzyme active site. 
 
Figure 22  
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In another example the four member azacyclic amino acid 9 was used as a ligand  for 
cadmium ion (Cd2+) forming a very stable complex 104. 29 The complex is so stable 
that this system is a very efficient method  to chelate the toxic cadmium cation in 
biological systems. 
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2 6-amino-3-azabicyclo[3.2.1]octane-6-carboxylic acids derivatives  
 
2.1   Introduction  
  
As reported in the previous chapter, constrained aza-bicyclo amino acids are 
noteworthy in particular for their different applications. Since the preparation of 
constrained amino acids and their possible applications are one of the main synthetic 
targets of our research group, during my thesis I planned the  preparation of a new 
class of rigid amino acids containing the aza-bicycle-octane scaffold, i.e. the 6-
amino-3-azabicyclo[3.2.1]octane-6-carboxylic acids named (ABOs) of general 
formula 105. 
 
Figure 24  
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The biological interest for aza-bicyclo octane ring  is evinced by the recent 
literature30 in which a large number of patents point out that this scaffold could be 
the pharmacophore of a bioactive molecule or a substituent of a different bioactive 
scaffold.  
Depending on the substitution pattern of the ring, different activities were reported. 
In particular,  many of these compounds were used for treating central nervous 
system disorders. Among these molecules, the carboxylic acid derivatives31, as well 
as the amino substituted compounds are of relevance.32 Some examples of these 
compounds are reported below. 
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Due to the importance of this scaffold we developed an efficient synthetic protocol 
for the  preparation of the new 6-amino-3-azabicyclo[3.2.1]octane-6-carboxylic 
acids, of general structure 105.  
 ABO can be considered both an α,γ- and α,δ-diamino acid containing sterical 
constraints and characterized by α,α-disubstitution. These features make ABO and 
their derivatives very promising molecules in view of their applications such as: 
• bioactive molecules tested on GABAA receptor  
• building blocks in peptidomimetic synthesis  
• ligands for transition metal  
• organocatalysts both in Diels Alder and Staudinger reactions  
 
2.2 6-Amino-3-azabicyclo[3.2.1]octane-6-carboxylic acids  
 
Four isomers of the ABO amino acid can be drawn and synthesized i.e. a couple of 
diastereoisomers each present as enantiomers (Figure 26) . The availability of all 
four ABO steroisomers is of importance in view of biological test.  
The synthetic protocol for the preparation of ABO amino acids was deeply studied 
aiming to optimize the synthetic procedure in term of : 
• minimization of the synthetic steps  
• minimization of cromathographic purification  
• orthogonal protection 
• preparation  of ABO compounds in multi gram scale  
• preparation of the four isomers in enantiomerically pure form starting from 
commercially available compounds 
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To ensure the preparation of stereomers 109, 109’ and 110, 110’ in enantiopure form, 
our retrosynthetic plan features the use of norbornene amino acids 111 and 112 as 
suitable starting materials.  
 
 Scheme 13 Retrosynthetic scheme. 
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Norbornene amino acids  111 and 112 are readily prepared as endo/exo 
diastereomers, both in racemic and in enantiopure form, by the Diels-Alder reaction 
starting from 2-aminoacrylate derivatives and cyclopentadiene 48. Compounds 111 
and 112 are very useful starting materials for the preparation of the aza compounds 
109, 110. In fact, by disconnection of C5-C6 bond into B ring of norbornenes 111, 
112 through an oxidative reaction, the cyclopentyl derivatives 113 and 114 (A ring in 
both compounds 111, 112 and 113, 114), substituted with the amino acid function 
and with two formyl groups with the proper regiochemistry and cis relationship, were 
obtained. From these key intermediates, the formation of the C ring of 109 and 110 
3-aza-bicyclo[3.2.1]octane skeleton was assured by a reductive amination reaction.  
The objects of these researches were published in: 
  
• Francesco Caputo, Cristian Cattaneo, Francesca Clerici, Maria Luisa Gelmi 
and Sara Pellegrino,J. Org. Chem., 2006, 71, 8467-8472  
• Maria Luisa Gelmi, Cristian Cattaneo, Sara Pellegrino, Francesca Clerici, 
Marina Montanari, Claudia Martini, J. Org. Chem., 2007 ,72 ; 9811-4. 
 
 
 
2.2.1 Synthesis of norbornene amino acid derivatives 
 
The preparation of methyl 2-acetamidobicyclo[2.2.1]hept-5-ene-2-carboxylate is 
reported in literature33 and shown in scheme 13. The key starting reagents for the 
preparation of the amino acids containing the 3-azabicyclo[3.2.1]octane skeleton 
were the norbornene derivatives exo-111a and endo-112a as well as the 
conresponding enantiopure compounds exo-111b and endo-112b. 
Instead enantiopure norbornene derivatives exo-111b and endo-112b were obtained 
by reaction of aminoacrylates 117 and cyclopentadiene 48 (Scheme 15). (-)-8-
Phenylmenthyl acrylate 117 is a know compound, which can be obtained in 47 % 
yield, according to the literature.34 To improve its yield, a new efficient protocol was 
adopted, by reacting 2-acetamidoacrylic acid 115 with dicyclohexylcarbodiimide 
(DCC) in dichloromethane under an inert atmosphere. The corresponding 4-
methyleneoxazolone 116 was obtained which is an unstable compound, very 
sensitive to moisture. For this reason, after filtration of the dicyclohexylurea under a 
nitrogen atmosphere and solvent elimination, oxazolone 116 was immediately made 
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to react in refluxing benzene with (-)-8-phenylmenthol in the presence of bis-
(dibutylchlorotin)oxide as the catalyst. Chiral acrylate 117 was obtained in an 
excellent yield (98%) (Scheme 14). 
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The asymmetric synthesis of the new cycloadducts exo-111 and endo-112 was 
carried out starting from enantiopure acrylate 117 performing the Diels–Alder 
reaction in dichloromethane as the solvent, Mg(ClO4)2 (0.3 equiv) as the catalyst and 
with ultrasound (14 h) (Scheme 15). A mixture of exo-111b and endo-112b (84%) 
was obtained in 83:17 ratio and with high diastereoselectivity for each exo (de 97%) 
and endo (de 96%) couple of diastereomers (HPLC analysis). Pure compounds exo-
111b (de 99%) and endo-112b (de 99%) were isolated by chromatographic 
separation and crystallization. 
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Scheme 15 
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The structure of cycloadducts exo-111b and endo-112b was determined by NMR 
experiments (1H, 13C, COSY, NOESY NMRs). 1H NMR spectra revealed differences 
between the two diastereomers: typical signals at 5.94–5.89 (m, H-6), 6.37–6.33 (m, 
H-5), 2.84 (m, H-4, H-1), 2.60 (dd, H-3exo), 1.15 (dd, H-3endo), 1.78 (m, H-7s), 1.38 
(m, H-7x), 4.88 (NH), and 1.76 (MeCO) are present for the exo-adduct. Signals at 
5.78–5.74 (m, H-6), 6.36–6.32 (m, H-5), 2.90 (br s, H-4), 1.76 (dd, H-3exo), 2.22 (dd, 
H-3endo), 2.56 (m, H-1), 1.67 (m, H-7s), 1.50 (m, H-7x), 5.42 (NH), and 1.93 (MeCO) 
characterize the spectrum of the endo adduct. As a confirmation of the 
stereochemistry assigned to the cycloadducts, a significative positive Overhauser 
effect (NOESY experiments) was observed between the NH and both H-3endo and H-
6 in the exo-adduct, and between the NH and H-7s in the endo-compound. 
The absolute configuration of all the stereocenters in compound exo-111b was 
assigned indirectly by the hydrolysis of the (-)-8-phenylmenthyl ester function to the 
corresponding acid. The known35 (-)-2-acetylamino-bicyclo[2.2.1]hept-5-ene-2-
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carboxylic acid exo-111b was obtained, characterized by the (1S,2S,4S)-
configuration. 
The stereochemical outcome of this reaction showed that the diene attacked the 
dienophile on the less hindered Si-face (intermediates A and B), which is in 
agreement with the results observed for the synthesis of the analogous (-)-menthyl36 
or (-)-8-phenylmenthyl derivatives.33 Accordingly, the stereochemistry assigned to 
the endo adduct (+)-112b is 1R,2S,4R. 
 
2.2.2 Synthesis of the 6-amino-3-azabicyclo[3.2.1]octane-6-carboxylic acids  and 
derivatives 
 
The synthesis of ABO derivatives was performed first, starting from racemic 
compounds exo-111a and endo-112a which  were transformed into the corresponding 
dihydroxy derivatives 118a and 119a by allowing 111a and 112a to react with N-
methylmorpholine-N-oxide (NMO) in acetone/H2O, in the presence of a catalytic 
amount of osmium tetroxide (Scheme 16). The diol derivatives exo-118a (86%) and 
endo-119a (84%) were obtained in pure form as single diastereomers characterized 
by the cis relationship between both the hydroxy groups and the bridge, as 
demonstrated by a NOESY experiment on exo-118a. In fact, spatial proximity 
between endo H-3 (δ 1.34) and H-5 (δ 3.73) and between H-6 (δ 3.97) and the methyl 
group of the acetyl group (δ 1.94) was observed.  
The cyclopentyl derivatives functionalized with two formyl groups with the proper 
stereochemistry were obtained by cleaving the C4-C5 bond of compounds 118a and 
119a with sodium periodate as the oxidant in dioxane/H2O (8:1) at room temperature 
(4 h). Bisaldehydes 120a and 121a were quantitatively obtained from exo-118a and 
endo-119a, respectively (Scheme 16). 
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Scheme 16 Synthesis of Bisaldehydes a 
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a
 Reagents and conditions: (i) OsO4, NMO, acetone/H2O, 25 C; (ii) NaIO4, 
dioxane/H2O, 25 C. 
 
The bisaldehydes are not very stable, and for this reason it was chosen to transform 
the crude reaction mixtures directly into the corresponding 3-azabicyclo[3.2.1]octane 
derivatives. A reductive amination was performed using p-methoxybenzylamine, as 
nitrogen donor, and sodium triacetoxyborohydride, as reducing agent (1.3 equiv). 
The reaction works at room temperature (4 h) in 1,2-dichloroethane and in the 
presence of a catalytic amount of acetic acid. Methyl 6-acetamido-3-
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azabicyclo[3.2.1]octane-6-carboxylate derivative exo-122a (61%) was obtained from 
120a. Compound endo-123a was isolated in 53 % starting from 121a. (Scheme 17). 
Scheme 17 Synthesis of 3-Azabicyclo[3.2.1]octane Ringa 
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a
 Reagents and conditions: (i) p-methoxybenzylamine NaBH(OAc)3, AcOH (cat.), 
ClCH2CH2Cl, 25 °C, (ii) MeNH2; NaBH(OAc)3, AcOH (cat.), ClCH2CH2Cl, 25 °C. 
This synthetic protocol suffers from some limitations related to (i) the efficiency of 
the exo/endo norbornenes 111 and 112 separation, and (ii) the necessity to perform 
the reaction twice, both starting from the exo and the endo norbornenes. For this 
reasons a more efficient synthetic protocol was developed by the preparation of the 
exo/endo mixture of compounds (±)-122a and (±)-123a  using the same synthetic 
procedure described for pure diastereoisomers, and in their easy separation by 
column chromatography in the final step (Scheme 17).The mixture of exo-111a and 
endo-112a (7:3) was transformed into a mixture of exo/endo-3-
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azabicyclo[3.2.1]octane amino acid derivatives exo-122a (41%) and endo-123a 
(15%), through the diol derivatives 118a, 119a and bisaldehydes 120a/121a.  
The above method was also applied to the preparation of the 3-N-methyl compounds 
(±)-exo-122c (24%) and (±)-endo-123c (11%), which were obtained in poor yields 
from the mixture of aldehydes 120a and 121a and using methylamine as a nitrogen 
donor in the standard reductive conditions (NaBH(OAc)3, AcOH (cat.), 
ClCH2CH2Cl, 25 °C) (Scheme 17).  
The enantiopure amino acids (-)-exo-122b (57%) and (-)-endo-123b (58%) (Scheme 
17) were prepared following the same synthetic protocol starting from enantiopure 
compounds (-)-exo-111b and (+)-endo-112b, transformed into the diol derivatives (-
)-exo-118b and (+)-endo-119b, oxidized to bisaldehyde 120b and 121b, respectively 
(Scheme 16). 
As reported above,  enantiopure compounds exo-111b and endo-112b were 
obtained in 83 : 17 exo/endo ratio through a Diels-Alder reaction and this result 
obviously disfavored the preparation of the endo series of compounds 123b when 
starting from (-)-phenylmenthyl ester endo-112b. For this reason and also 
considering the possibility to synthesize all stereomers of compounds 122 and 123, 
we chose to start from racemic methyl esters of exo-111a and endo-112a which can 
be prepared in 70:30 ratio and in grams scale.37 
 
Following the above reported procedure, the mixture of compounds 111a and 112a 
was transformed into the four enantiopure stereoisomers exo-124b (25%), exo-124b' 
(28%), endo-125b (12%), and endo-125b' (10%). The preparation of the above 
amino acids was performed on the gram scale (7 g), using the cheaper of (+)-(R)-1-
phenylethylamine as nitrogen donor and resolving reagent when the reductive 
amination reaction (NaBH(OAc)3, AcOH (cat.), ClCH2CH2Cl, 25 °C) was performed 
from aldehydes 120a, 121a (Scheme 18).  
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Scheme 18 Reductive Amination Procedurea. 
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a
 Reagents and conditions: (i) (+)-(R)-1-phenylethylamine, NaBH(OAc)3, AcOH 
(cat.), ClCH2CH2Cl, 25 °C. 
 
 
2.2.3 Studies on the deprotection and functionalization of the N-3 atom. 
 
In order to prepare a series of ABO derivatives characterized by a different 
substitution pattern on N-3, which are useful for biological tests, both 3-NH- and 3-
N-alkyl compounds were prepared. 
The p-methoxybenzyl derivatives exo-122a and endo-123a (Scheme 19) were first 
selected as key reagents aiming to find a general procedure to minimize the synthetic 
steps. This allowed the NH-compounds as well as a series of N-alkyl compounds to 
be synthesized efficiently.  
Aiming to prepare the NH azabicyclo[3.2.1]octane derivatives, which are also 
valuable and alternative starting materials for the preparation of 3-N-substituted 
amino acids, the N-p-methoxybenzyl group (PMB) on compounds exo-122a was 
removed by an oxidative process using cerium ammonium nitrate (CAN) in 
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acetone/H2O (9:1) at room temperature. This method is reported in the literature, but 
its straightforward application in the present case caused difficulties because of the 
solubility of the amino acid derivative in water. The problem was overcome by 
treating the reaction mixture with solid NaHCO3 followed by its chromatography on 
silica gel. Compound exo-126a was isolated in 90% yield. The same synthetic 
protocol allowed us to transform endo-123a into amino acid endo-127a (62%) 
(Scheme 19). 
 The deprotection of N-3 was also performed by hydrogenolysis which made possible 
an easy purification and better reaction yields of the products (Scheme 19). The 
hydrogenolysis of (±)-exo-122a and (±)-endo-123a (Pd/C, MeOH, 25 °C, 1 atm, 2 
days) gave the NH derivative (±)-exo-126a (97%) and (±)-endo-127a (93%), 
respectively.  
 
Scheme 19 Orthogonal deprotection of the N-3 amino function a 
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a
 Reagents and conditions: (i) CAN, acetone/H2O, 25 °C; (ii) Pd/C, H2, MeOH, 25 
°C, 1 atm, 2 days 
Since, as reported before, the preparation of N-methyl derivatives from aldehydes 
120a and 121a gave pure results in term of yield, an alternative and more general 
procedure was planned to prepare, in general, N-alkyl compounds. This synthetic 
target  was achieved using  a "one pot" deprotecton and alkylation reaction of the 
nitrogen atom on N-3, taking advantage of the use of catalytic hydrogenation in 
presence of a carbonyl compound, starting from reagents 122a and 123a or 
enantiopure compounds 124/124' and 125/125'.  
When the hydrogenolysis was performed in presence of a methanolic solution of 
formaldehyde (37%), the N-methyl derivatives (±)-exo-122c (74%) and (±)-endo-
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123c (70%) were isolated, respectively, from (±)-exo-122a and (±)-endo-123a 
(Scheme 17). It has to be emphasized that this synthetic approach is a valuable 
alternative to the reductive amination of bis-aldehydes 120a and 121a in the presence 
of MeNH2 which gave the same N-methyl derivatives 122c and 123c but in very low 
yield (Scheme 17). The reductive alkylation of (±)-exo-122a was also performed in 
EtOH/acetaldehyde and in acetone and the expected N-ethyl and N-isopropyl 
derivatives (±)-exo-122d (93%) and (±)-exo-122e (86%) were isolated, respectively 
(Scheme 20). Compound (±)-endo-123d (85%) was obtained from (±)-endo-123a. 
 
 
Scheme 20  Synthesis of 3-N-Alkyl-6-amino-3-azabicyclo[3.2.1]octane-6-carboxylic 
Acids by a "One-Pot" Deprotection-Alkylation Procedurea 
RN
COOMe
NHCOMeMeOOC
MeCONH
NR
 (±)-endo-123a
(±)-exo-122c: R = Me
(±)-exo-122d: R = Et
(±)-exo-122e: R = i-Pr
(±)-endo-123c: R = Me
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i
MeOOC
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a
 Reagents and conditions: (i) H2, Pd/C (122c,123c: MeOH/HCHO; 122d,123d: 
EtOH/MeCHO; 122e: MeCOMe) 
The "one-pot" deprotection-methylation reaction of the N-3 atom of the four 
stereoisomers (+)-exo-124, (-)-exo-124', (+)-endo-125, and (-)-endo-125' using 
formaldehyde gave the pure enantiomers (+)-exo-122c (80%), (-)-exo-122c' (70%), 
(+)-endo-123c (83%), and (-)-endo-123c' (85%), respectively (Scheme 21).  
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Scheme 21  Enantiopure 6-Amino-3-azabicyclo[3.2.1]octane-6-carboxylic Acids and 
Their 3-N-Methyl Derivativesa 
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a
 Reagents and conditions: (i) R = Me: H2, Pd/C, MeOH, HCHO; (ii) 6 N HCl,∆. 
Finally, considering that the 4,4-diphenylbut-3-en-1-yl group is a typical residue that 
increases selectivity (see compound SK&F 89976-A) on GABA receptors and taking 
into account that the appropriate aldehyde is not available, compound (±)-exo-122g 
(30%) was prepared starting from (±)-exo-126a and 4,4-diphenylbut-3-en-1-yl 
bromide operating in DMF and in the presence of K2CO3 and NaI (Scheme 22).  
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Scheme 22. Synthesis of 3-N-(4,4-diphenylbut-3-en-1-yl)-6-amino-3-
azabicyclo[3.2.1]octane-6-carboxylic Acids a 
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i ii
(±)-exo-129g
2HN
N
2(Ph)C=HC(H2C)2
HOOC
(±)-exo-126a
* 2 HCl
 
a
 Reagents and conditions: (i) (Ph)2C=CH(CH2)2Br, K2CO3, NaI, DMF; (ii) 6 N 
HCl,∆;  
 
2.2.4 Selective deprotection of amino acid function  
Methyl ester group of (±)-exo-122a and (±)-endo-123a was selectively hydrolyzed 
using basic conditions (EtOH/KOH). The corresponding acids (±)-exo-132 (95%) 
and (±)-endo-133 (99%) were isolated, respectively (Scheme 23). 
Both the amino and the carboxy functions were deprotected in acid conditions (6 N 
HCl at 100 °C, 24 h). Amino acids exo-134a ,134d, 128a endo-135a, 129a were 
obtained in quantitative yield, as bishydrochlorides, from (±)-exo-122a ,122d, 122a  
(±)-endo-123a, 127a respectively (Scheme 23). The same protocol was also used 
efficiently (6 N HCl at 100 °C, 36 h) to deprotect the phenethyl derivatives (+)-exo-
124 and (-)-exo-124', (+)-endo-125 and (-)-endo-125’, obtaining compounds (+)-exo-
137 and (-)-exo-137' , (+)-endo-138 and (-)-endo-138’ respectively (Scheme 23). 
Compounds (+)-exo-122c and (-)-exo-122c', (+)-endo-123c and (-)-endo-123c’, were 
also hydrolysed obtaining compounds (+)-exo-128c and (-)-exo-128c' , (+)-endo-129 
and (-)-endo-129c’ respectively (Scheme 21).  
The hydrolysis of ester functions of compounds (±)-exo-122a and (±)-endo-123a was 
successfully achieved with KOH in EtOH (reflux for 50 h).  Amino acids (±)-exo-
132 (45%) and (±)-endo-133 (60%) were obtained respectively. (Scheme 23) 
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Scheme 23 Orthogonal Deprotectiona 
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(+)-exo-137: R' = Phenethyl
(-)-exo-137': R' = Phenethyl
i
(±)-exo-132: R' = PMB
i
(±)-endo-123a: R' = PMB
(±)-endo-127a: R' = H
(+)-endo-125: R' = Phenethyl
(-)-endo-125': R' = Phenethyl
(±)-endo-135a:  R' = PMB
(±)-endo-129a:  R' = H
(+)-endo-138: R' = Phenethyl
(-)-endo-138': R' = Phenethyl
ii
 
a
 Reagents and conditions: (i) 6 N HCl, 100 °C;  (ii) KOH, EtOH (95%), 120 °C 
2.2.5 Stereochemical assignment for N-phenethyl derivatives  
Aiming to ensure the correct stereochemistry of each stereoisomer of the phenethyl 
series, isomers (-)-exo-122f' and (+)-endo-122f were hydrolyzed in 6 N HCl (100 °C, 
24 h) to give (-)-exo-130’ and (+)-endo-131, respectively, in quantitative yield as the 
bishydrochlorides (Scheme 24). Compounds (-)-exo-130’ ([α]D = -9.3) and (+)-endo-
131 ([α]D = +4.9) were correlated to the same compounds (-)-exo-130’ ([α]D = -9.0) 
and (+)-endo-131 ([α]D = +4.0) derived from the catalytic hydrogenolysis (Scheme 
24) of the known amino acids (-)-exo-132’ and (-)-endo-133 followed by their 
treatment with anhydrous HCl. 
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Scheme 24: Stereochemical assignment a  
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  [α]D =  + 4.9                                   [α]D =  + 4.0                                         [α]D =  - 9.0                               [α]D = - 9.3 
aReagents and conditions: (i) H2, Pd/C, MeOH; (ii) 6N HCl, ∆; (iii) Na, MeOH at    0 
°C, then 100 °C; (iv) 6N HCl, r.t.  
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2.2.6 Spectroscopic characterization   
All compounds were characterized by spectroscopic data (1H NMR, 13C NMR, 
COSY, NOESY; Hetcor) and, as examples, the spectra of compound 122a  and 123a  
are here detailed. It is proposed a predominant chair-envelope conformation for 3-
azabicyclo[3.2.1]octane from which it is evinced that the benzyl group is in the 
equatorial position.38, 39 Accordingly, we assumed that the more probable 
conformation of compounds 122a is that shown in Figure 28. 
Figure 28 . Conformation and selected NOESY interactions for compounds 
122a/123a 
MeO
N
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Hax
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H H
H
H
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exo-122a X = NHCOMe; Y = COOMe 
endo-123a X = COOMe; Y = NHCOMe 
Typical signals for compound exo-122a are at δ 1.50 (Heq-8) and 2.00 (Hax-8) and at 
δ 2.20 (H-1) and 2.72 (H-5). Methylene protons resonate at δ 2.35 (Hβ-2), 2.80 (Hα-
2), 2.00 (Hβ –4), 2.53 (Hα-4), 2.35 (Hx-7), 1.72 (Hn-7) confirming the formation of 
constrained ring. An AB system at 3.55, 3.17 δ (J = 12.5 Hz) characterizes the 
presence of the benzyl protons. Selected signals in the 13C NMR spectrum are δ 65.9 
(C-6), 62.2 (CH2Ar), 61.0 (C-2), 55.6 (MeOAr), 54.9 (C-4), 52.5 (MeO), 42.0 (C-7), 
40.0 (C-5), 37.1 (C-8), 34.7 (C-1), 22.5 (MeCO). 1H NMR spectrum of  
diastereoisomer endo-5a shows signals δ 3.42, 3.33 (CH2Ar), 3.01 (Hn-7), 1.90 (Hx-
7), 2.84 (Hα-4), 2.18 (Hβ –4), 2.71 (Hα-2), 2.02 (Hβ –4), 2.27 (H-1), 2.19 (H-5), 2.01 
(Hax-8), 1.51 (Heq-8). The equatorial position of H-8 was univocally assigned through 
a COSY experiment. In fact, it is evinced a coupling with Hn-7 at 3.01 (J = 1.8 Hz). 
 50
The carbon atoms resonate at δ 8.5 (C-6), 62.0 (CH2Ar), 59.0 (C-2), 55.9(C-4), 55.6 
(MeOAr),  52.5 (MeO), 46.8 (C-5), 39.9 (C-7), 37.1 (C-8), 35.1 (C-1), 23.7 (MeCO). 
NOESY experiments confirmed the assigned configuration. Significant special 
proximity on exo-122a was observed between Horto protons of aryl ring at (δ 7.16) 
and Hα-2, Hα-4, and most of all, with NH (δ 6.44) and Me of acetamido group (δ 
1.59). Overhauser effect was observed in compound endo-122a between Horto 
protons of aryl ring at (δ 7.26) and proton of CH2 groups at lower field (Hα-2: 2.71; 
Hα-4: 2.84; Hn-7: 3.01 δ) and Me group of carbonylic function (3.69 δ). Furthermore, 
the NH group shows an Overhauser effect with Hax-8. 
2.3 Biological evalutation of 6-Amino-3-azabicyclo[3.2.1]octane-6-carboxylic acids 
and derivates  
Compounds 105 can be considered constrained analogues of γ-aminobutyric acid 
(GABA), the major inhibitory neurotransmitter in the vertebrate central nervous 
system. GABAergic neurotransmission, which is mediated through the activation of 
three receptor subtypes (GABAA, GABAB and GABAC),40 has been implicated in 
many physiological (feeding, cardiovascular regulation) as well as pathological 
(epilepsy, alcoholism, schizophrenia, sleep disorders, depression and anxiety) 
events.41 GABAA receptor gates a Cl--selective channel in response to the binding of 
the transmitter and contains multiple sites for pharmacologically distinct classes of 
allosteric modulators. GABAA receptor–mediated Cl- conductance is positively 
modulated at the GABA recognition site, as well as at allosteric sites that bind 
benzodiazepine, barbiturates, and steroids.42 
Selective targeting and modulation of GABA transporter subtypes is of biological 
interest and additionally of fundamental importance for the elucidation of their 
specialized physiological function and individual structure. Different constrained 
amino acids have been prepared and tested on GABA receptors and it was found that 
the stereochemistry and the substituent linked to nitrogen atom are important features 
to increase selectivity and activity. Between them, nipecotic acid 138 and guvacine 
139 are inhibitors of GABA transport with anticonvulsant activity,43,44 as well as 
several potent GABA uptake inhibitors including tiagabine 137c45 and SK&F 89976-
A 137b46 which are selective molecules for GAT-1. Recently, derivatives of 
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piperidine-3-alkanoic acids 137d, characterized by highest affinity at GAT-3, were 
prepared.47  
 
Figure 29 
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Considering the general biological interest toward new derivatives possessing 
affinity for GABA receptors, we planned the biological evaluation of GABA mimic 
amino acids containing the azabicyclooctane skeleton. 
 
2.3.1 Biological results 
 
Amino acids 134a, 128c, 128c’, 128a, 129g, 132’, 135a, 129c, 129c’,129a, 133, as 
well as some of the corresponding N-acetyl derivatives (see Table 4) were tested for 
their binding activity on GABAA receptors in rat cerebral cortical membranes using 
labelling tests with [3H]muscimol (for GABAA sites) and [3H]flunitrazepam (for the 
 52
benzodiazepine site). The binding affinity of newly-synthesized compounds was 
determined in rat cerebral cortical membranes by competition experiments. Aliquots 
of the membrane preparation (~100 µg protein) were incubated in 50 mM Tris-citrate 
buffer (pH 7.1) at 0 °C for 90 min with [3H]muscimol (5 nM) and the tested 
compound (10 µM); nonspecific [3H]muscimol binding was determined in the 
presence of 100 µM GABA. Radioactivity bound to membranes was determined after 
rapid filtration. 
Table 4 Binding affinity of compounds 134a, 128c, 128c’, 128a, 129g, 132’, 135a, 
129c, 129c’,129a, 133 on GABA receptors 48 
HO2C
R1 NH
NR 2
 
 
R1/R2 
% 
Inibition 
(10 µM) R 2N
CO2H
NHR1
 
 
R1/R2 
% 
Inibition 
(10 µM) 
(±)-exo-134a R1 = H, R2 = PMB ni (±)-endo-135a R1 = H, R2 = PMB ni 
(+)-exo-128c R1 = H, R2 = Me 14 (+)-endo-129c R1 = H, R2 = Me 7 
(-)-exo-128c' R1 = H, R2 = Me ni (-)-endo-129c' R1 = H, R2 = Me ni 
(±)-exo-128a R1 = R2 = H ni (±)-endo-129a R1 = R2 = H ni 
(±)-exo-129g R
1
 = H, R2 = 
(Ph)2C=CH(CH2)2 ni - - - 
(±)-exo-132 R
1
 = COMe, R2 = 
PMB ni (±)-endo-133 
R1 = COMe, R2 = 
PMB ni 
 
In general these compouds do not display an appreciable affinity for GABAA 
receptor. Only N-Me derivatives 128c and 129c displayed low affinity for GABAA 
receptors and in particular, the biological activity is solely due to the (+) enantiomer 
(i.e. (+)-(1R,5R,6R)-exo-128c and (+)-(1R,5R,6S)-endo-129c) thus confirming that 
the stereochemistry of the skeleton is an important feature in the binding with GABA 
receptors. 
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3 ABO in peptidomimetics  
 
3.1 Introduction 
 
One of the finality of my thesis concern the use of ABO unnatural amino acids in 
peptide synthesis. In particular we were interested to insert these amino acids in short 
peptide sequences aiming to evaluate their ability to induce a secondary structure. 
The features of these compounds, i.e. the presence of constraints and 
heterosubstitutions, make them suitable for this kind of application. ABO compounds 
are members of the family of Ciα ↔ Ciα  cyclized, Cα tetrasubstituted α-amino acids 
(ACnC: 1-aminocycloalkane-1-carboxylic acids). The use of Cα,α-disubstituted 
glycines in the synthesis of peptides with restricted conformational flexibility has 
acquired increasing importance in the design of analogues of bioactive compounds. 
In fact, it is well known that Cα tetrasubstituted amino acids belonging to this class 
are able to reduce drammatically the available conformational space by stabilizing 
specific secondary structures,49,50 such as β-51,52,53 and γ-turns54,55 and 310- and α-
helixes.56,57 The main rapresentative of this class of amino acids is Aib 140 (α-
aminoisobutyric acid) and its congeners such as  compounds 141, 142-145 ( reported 
in Figure 30).58  
 
Figure 30 
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Aib has been use since 196459 for the preparation of  peptides because it was shown 
that in general it favours α- or 310-helix, which are the two most prevalent helices 
found in proteins60, 61. The 310-helix, which accounts for approximately 10% of all 
protein helical structures, is considered to be a protein folding intermediate to the α-
helical conformation. 
The backbone torsional angles (φ, ψ) of Aib and several other α,α-dialkylated amino 
acids are severely restricted, resulting in the pronounced propensity of this residue to 
favor helical structures, even in short peptides.62, 63,64 
In this context the family of the Ac,c 146 (l-amino-1-cycloalkane-carboxylic acid, n 
= 1-6, 9) alicyclic residues proved to be valuable in the preparation of 
conformationally constrained peptide backbones.  
 
Figure 31 
146
NH2
COOH
n
n = 1-6,9
NH2
COOH
147
NH2
COOH
148
 
 
More specifically, the three-membered ring Ac3c residue compounds 146 (n = 1) and 
14765 exhibits a marked preference for the bridge region of the conformational space, 
charaterized by  φ = ±90, ψ = 0°. This small-ring residue can also be accommodated 
in distorted type III (III') β-turns and 310-helices. Interestingly, however, the 
preferred conformations [regular type III-(III') β-turns and 310-helices],66 found for 
Ac4c-Ac9c and Ac12c residues, having the cyclic moieties significantly larger than 
that of Ac3c, are closely parallel to those of Aib. The conclusion of these studies are 
that  the alicyclic Cα,α-disubstituted glycines Ac,c with n = 1-6, 9 have different 
effective volume and hydrophobicity, but they exhibit a strictly comparable 
conformational preference.  
Among Ciα ↔ Ciα  cyclized, Cα tetrasubstituted α-amino acids, few example of 
nitrogen containing ring are reported in the preparation of peptide, i.e. the achiral 
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piperidine-4-amino-4-carboxylic acid Api 149 and derivatives,67 and its correspnding 
N-oxide (TOAC68,69).  
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3.2 Synthesis of peptides  
 
The synthesis of peptides containing multiple α,α-bisubstituted amino acids are 
inherently difficult due to severe steric hindrance caused by tetrasubstitution at the α-
carbon. For this reason, studies on the synthesis of peptides rich in ABO, both in 
solid phase and in solution, were performed. This part of my research was developed 
in collaboration with the German group of Dr. Chiara Cabrele of the University of 
Regensburg (Germany) who introduced me in this field of chemistry. Peptide 
sequences can be synthesized  by two different techniques: 
 
(i) solid phase synthesis (SPPS) 
(ii) solution phase synthesis (SPS) 
 
Each of these methodologies has intrinsic advantages and disadvantages and it is 
commonly thinking that one is the complement to the other one. 
Even if the most useful techniques for the chemical peptide synthesis is the solid 
phase, especially when it is necessary to synthesized long peptide sequences, the use 
of a very steric hindered amino acid residues generally gives better reaction yields 
operating in solution.   
In the solid phase methodology using a Fmoc strategy, the peptide grows up over a 
solid polymeric support and therefore, after each coupling step, the by-products are 
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simply removed by filtration and washing. Furthermore, because of the repetitive 
nature of this synthesis (deprotection, washing, coupling, washing, deprotection, …), 
the use of an insoluble support in a single reaction vessel allows  the easy 
automatization of the process. 
 
Scheme 25 
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In contrast, the solution phase synthesis is not so versatile. In fact, the peptide grows 
up in solution and, after each step, the purification of the growing peptide is more 
complicated. Furthermore all the tedious coupling process cannot be automatized. 
For these reasons this method found application in the preparation of small peptides 
or to join pre-synthesized  peptide sequences.  
In particular, this synthetic methodology presents some advantages since the 
coupling of “difficult sequences“ can be better controlled. This methodology is 
indicated for the coupling with steric hindered amino acids for which the yield of 
coupling is very low. Solution phase synthesis is based on the use of the acid-labile 
tert-butyl carbamoyl (Boc) group for the protection of the α-amino group, thereby 
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allowing the orthogonal protection of side-chain groups through the use of a basic-
labile protection. 
 
Figure 33 
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3.2.1 ABO in peptide synthesis  
In the preliminary studies we chose to start from the more available enantiopure 
compounds exo 124 and 124’ which were used as α-amino acids. 
 
Figure 34 
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3.2.2 Use of 124 or 124’  as α-amino acids. 
 
It is well known  that the N-acetyl and the O-methyl protecting groups were not 
useful as protecting groups for the peptide synthesis, due to the too hard cleavage 
condition. For this reason, we replaced these groups with more useful functions. 
As reported before in scheme 23 starting from 124 and 124’, the hydrolysis of both 
amino and carboxy groups give compounds 137 and 137’. In order to investigate the 
behaviour of the ABO scaffold both in solid phase and in solution phase peptide 
synthesis, we prepared compounds the Fmoc derivatives 152’, and the Boc protected 
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compounds 153’ and 153 starting from  compounds 137’. The free amino function 
was protected using Fmoc-OSu in presence of an aqueous solution of  NaHCO3 and 
1,4-dioxane. The reaction works overnight at 25 °C, giving the corresponding 
compounds 152’ (70%). Alternatively, we protected the free amino function of the 
compounds 137 and 137’ using Boc-anhydride in aqueous NaOH and t-BuOH. The 
solution was stirred at 25 °C overnight giving the corresponding compounds 153 
(60%) and 153’ (58%),  respectively.  
 
Scheme 26: Boc and Fmoc Protectiona 
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a
 i) Boc anhydride in a ButOH/NaOH aqueous solution, 25 °C, overnight; ii) 
FmocOSu (N-(9-Fluorenylmethoxycarbonyloxy) succinimide) in dioxane 
solution/NaHCO3 aqueous solution, 25 °C, overnight 
3.2.3 Solid phase peptide synthesis (SPPS) 
 
In order to understand the reactivity of compound  (-)-exo-FmocABO 152’ by the 
solid phase coupling condition, we planned the synthesis of the sequence 154.  
Figure 35  
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In the sequence 154, thyrosine was inserted making possible to calculate the exact 
concentration of the peptide in solution by a simple UV/VIS analysis, since is know 
its ε (estintion molar coefficient). Furthermore glycine, was the spacer between the 
thyrosine and the peptide, containing the ABO-Ala sequence.  
The synthesis of 154 (Figure 36) was carried out by manual solution coupling on 
Rink amide (MBHA resin (loading 0.58 mmol g-1) which is in the Fmoc-protected 
form. For this reason, to obtain N-free linker, the resin was first treated with 
piperidine in DMF/NMP (80:20 v/v).  
 
Figure 36  Rink amide MBHA resin 
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The natural amino acids of this sequence (L-Tyr, L-Ala and Gly), were coupled 
activating in situ the carboxylic function with HBTU (3.9 equiv.), HOBt (4 equiv.) in 
DMF in the presence of DIPEA (8 equiv.). The (-)-exo-FmocABO was coupled using 
different conditions, i.e. HBTU (2.2 equiv.), HOAt (2.2 equiv.), instead of HOBt, in 
DMF in the presence of DIPEA (5 equiv.). Every coupling reaction is also followed 
by an acetylation reaction to block the incomplete coupling reaction. Fmoc cleavage 
was accomplished by treating the peptidyl-resin with 20% piperidine in DMF. 
To control the progress of the synthesis, small scale cleavage was performed and the 
resulting sample was analyzed by MALDI-TOF-MS. The last step of the synthesis 
was the N-terminal acetylation using acetic anhydride (5 equiv.) and DIPEA (2.5 
equiv.). Final cleavage of the peptide from the resin and simultaneous side-chain 
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deprotection was achieved by treatment with a TFA/water/triisopropylsilane (TIS) 
mixture (90:5:5) for 2.5 hours. 
The purification of the peptide was difficult. First the peptide mixture was treated 
with cold diethyl ether, centrifugation and further three ether-washing/centrifugation 
cycles to remove the scavengers. In these steps we have many problems since our 
final compound 154 is a very apolar compound which was partially soluble in ether. 
For these reasons we obtained a dirty mixture and in few amount. The mass analysis 
reveal the presence of the expected product but other picks corresponding to the 
incomplete ABO coupling were also detected.  
To overcome this problem we tried to synthesized the sequence 155 in which we 
replaced the L-alanine with a L-lysine aiming to increase the polarity end to promote 
the precipitation process. Unfortunately, we were not able to obtain sequence 155 
probably for steric problems.  
Figure 37 
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3.2.4 Solution phase synthesis (PSS) 
To better study the ABO reactivity and the yield of each coupling step, we have 
developed the synthesis of a short peptide sequence using a Boc solution phase 
synthesis. We started to synthesized the short penta-aminoacidic sequence 156  
containing the repetition of ABO-Ala. 
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a 
reaction conditions:  i) EDC (10 eq.)/HOBT (10 eq.)/DIPEA(15 eq.) in CH2Cl2, 25 
°C for 2 days; ii) TFA/CH2Cl2 (1 : 2), 25 °C for 24h. 
 
Each coupling step was performed in CH2Cl2 using as coupling reagents EDC (10 
eq.), HOBT (10 eq.) and DIPEA(15 eq.). The coupling reactions works in 2 days 
allowing to give pure peptide after washing the crude mixture with water, drying 
over Na2SO4 and column chromatographic purification on SiO2. The Boc-cleavage 
was performed using a solution of TFA/DCM (1:2, reaction time 24h). After 
neutralization the product  was extract and analyzed without further purification. 
Using this synthetic protocol we synthesized step by step compound 156. 
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3.3  Spectroscopical characterization of ABO-peptides   
Peptides 158, 161, 164, and 156 were studied performing analytic and spectroscopic 
experiments. The mass (ESI) experiments confirmed the molecular weight of each 
peptide. 
The dipeptide 158 (Figure 38) was characterized by  spectroscopic data (1H NMR, 
13C NMR, COSY, NOESY; Hector). The results are reported in Table 6 . 
Figure 38 
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Table 6  NMR data of the dipeptide 158 
Residue 
 
atom δ1H Multiplicity J (Hz) δ 
13C Noesy/Roesy 
CO   175.0  
1 2.18-2.08 overlapped 34.3  
2α 2.83-2.75 m MeCH(m), H-7n(vw) 
2β 2.18-2.08 overlapped 56.5  
4α 2.58 d, J 10.6 H-5(w) 
4β 1.91 d J 11.4 53.3 H-5(m), H-2β(w) 
5 2.3 brs 41.0 H-4α(w) 
6   66.1  
7x 2.5   
7n 1.60 d, J 13.2 
39 
overlapped H-2α(vw), 
8a 1.69 brs  
8e 1.15 d, J 7.3 36.3 H-4β(m), H-5 
PhCH 3.38-3.36 m 63.7 H-5 
MeCH 1.26 d, J 6.5 20.1 H-2α(s), H-4α(vw) 
1 
Arom 7.35-7.20 m 127.3, 127.8 128.9, 144.9 
MeCH(s), MeC, H-
4β(vw), H-4α(w) 
 63
NH 6.28 brs  Arom, NHAla(vw), H-7n, H-4α 
Me 1.40 s 28.8  
C   78.7  
 
Boc 
CO   155.7  
CO   173.7  
CH 4.25-4.19 m 64.7 MeAla 
Me 1.21 d, J 6.7 17.8  
NH 7.67 d, J 7.5  H-5, CHAla, MeAla, NHABO(vw) 
 
 
2 
OMe 3.58 s 52.4  
 
In particular, NOEs effects were observed between H-4β and H-2β, between H-8e 
and H-4β and between H-7n and H-2α. These spatial proximity allowed to assigned 
unequivocally the chemical shift to each proton of the ring. These results are in 
agreement with the NOEs observed for simple ABO compounds 70 where H-2α, H-
4α, H-7x and H-8a resonate at low field with respect to their counterpart. This 
observation was used for the assignment of the ABO-protons for the other peptides 
when the certain stereochemistry could not be assigned since the signals are 
overlapped.  
Spatial proximity was also observed between  the two NH, between NHAla and H-5 
and between both the methyl and NH of Boc group and aromatic protons. 
 
The NMR data of  compound 161 were reported in Table 7. The more significant 
NOEs correlations are resumed in the Figure 39. 
 
Figure 39  Tripeptide 161 
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Table 7 the NMR data of the tripeptide  161 
Residue atom δ 1H 
Molteplicity 
J (Hz) δ
 13C Noesy 
CO   173.01  
CH 3.44 q, J 6.9 49.9 Arom(7.35,w), H-4(2.38,s; 2.72,vw), Me(1.33) 
Me 1.33 d, J 7.0 20.7  
1 
 
NH2 1.70 overlapped  NHABO(8.50-7.80,vw) 
CO   176.31  
1 2.25 brs 32.9 H-8e(1.15,s) 
2α 2.80 brs  
2β  2.33 d, J 10.1 54.2  
4α    2.72 d, J 13.4 Arom (7.36,vw) 
4β  2.38 d, J 11.5 52.4 Arom (7.36,m) 
5 2.90 brs 40.1 NH (7.49), MeAla3(1.38,s), H-8(2.1,s), H-4(2.72,w), 
6   65.7  
7x 2.69 d, J 13.4  
7n 1.90-1.70 m 39.4 brs  
8a 2.20-1.98 m MeAla3(1.38,w), H-1 
8e 1.38 overlapped 35.4 MeAla3(1.38,w) 
PhCH 3.66 q, J 6.4 63.4 MeCH(1.44) 
MeCH 1.44 d, J 6.4 15.5  
Arom 
7.42-
7.33(o,m) 
7.33-7.28 
(p) 
m 
141.4(C), 
127.6, 
127.3, 
126.7(p) 
MeCH(1.44), H-4(2.38,s, 
2.72,vw), CH
 Ala1 (3.44) 
2 
 
NH 8.50-7.80   CH Ala1(3.44, vw), NH2(1.70,vw)2 
CO   172.91  
CH 4.52-4.46 m 47.5 NHAla3(7.45,s), Me (1.38,s) 
Me 1.38 d, J 7.1 17.4 NHAla3(7.45,s), H-8, H-5(w) 
NH 7.45 d, J 6.9  H-5(m), H-7, MeAla3(1.38,s), CHAla3(4.50,m) 
3 
OMe 3.72 s 51.5  
a
 spectra in CDCl3 1The carbonyl chemical shifts are tentatively assigned; 2exchange 
pick. 
 
To achieve the better resolution regarding the proton chemical shifts of tetrapeptide 
164, differents solvent were tested (CDCl3, CD3CN) and CD3CN was then selected. 
Using NMR analyses (1H, 13C, TOXY, COSY, HSQC, NOESY and HMQC, see 
Table 8) we first unequivocally assigned all chemical shifts to each atom. 
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Figure 40 Tetrapeptide 164 
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Table 8  the NMR data for the Tetrapeptide 164 
Residue atom δ 1H Molteplicity J (Hz) δ
 13C Noesy HMBC 
CO   173.2   
1 1.80-1.70 brs 33.1   
2α 2.90-2.78 brs  
2β  2.25 overlapped 54.9 brs MeCHABO1(1.35)  
4α  2.52 d, J 11.7 PhCHABO1(3.59-3.51), MeCH or H-8  
4β   2.17 overlapped 
52.3 
 
 
5 2.58 brs 40.2 H-8aABO1(1.30), H-8aABO1(1.96)  
6   65.2 brs   
7x 1.77  H-7nABO1(2.41,vw) 
7n 2.41 d, J 12.9 39.9 brs H-7xABO1(1.77,vw) 
 
 
8a 1.30 overlapped   
8e 1.96 overlapped 35.3   
PhCH 3.59-3.51 brs 63.9 br MeCHABO1(1.36,s), H-4αABO1 (2.52,w)  
MeCH 1.39-1.34 brs 16.3   
Arom 7.40-7.28 m 
127.9-
126.1 
(C)142.
9 
  
1 
Broad
 
 
 
NH2 2.251 overlapped    
CO   171.9  CHAla2(4.15, vw), MeAla2(1.33s) 
2 
 
CH 4.24-4.15 m 48.5 
Arom(7.36, 7.31), 
MeAla2(1.33,s), 
NHAla4(7.08,vw), 
NHAla2(7.82,s) 
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Me 1.33 d, J 7.0 16.9 CHAla2(4.24-4.15,s) CHAla2(4.24-4.15,w) 
 
NH 7.82 brs  CHAla2(4.24-4.15,s)  
CO   177.1  H-7xABO3(2.40) 
1 2.22 brs 34.3   
2α    2.99 dd, J 10.4, 3.9 
arom (vw), 
PhCHABO3(3.48,m), H-
7n
 ABO3(1.46,m), 
MeABO3(1.40,s) 
2β      2.29 d, J  = 10.3 
55.5 
 
C-4ABO3(52.8,w)/C-
8ABO3(vw), H-
7xABO3(2.40,s) 
4α    2.78-2.73 m 
H-4βABO3(2.06), 
PhCHABO3(3.48), 
MeCHABO3 (1.40) 
PhCHABO3(w), H-
2αABO3(2.99,w) 
4β     2.06 d, J 11.1 
52.8 MeAla2(1.33,m), 
PhCHABO3(3.48,s), H-
4αABO3(2.75,s), Arom 
(7.36w) 
C-8ABO3(36.7,vw) 
5 1.97 overlapped 42.8  H-4αABO3(2.75,w) 
6   64.1  H-7xABO3(2.40), H-4βABO3 (2.06) 
7x 2.40 d, J 12.9  H-2βABO3(2.29,s) 
7n 1.46 dd, J 13.0, 2.0 43.0 H-2αABO3(2.99,m) C-8 ABO3(36.7), C-2(55.5,vw) 
8a 2.18 overlapped  
H-2βABO3(2.29,w), 
H-4βABO3 (2.06,w), 
H-7nABO3(1.46,w) 
8e 1.35 overlapped 
36.7 
  
PhCH 3.48 q, J 6.8 64.0 
H-2βABO3(2.99,m), H-
2αABO3(2.29,m), H-
4αABO3 (2.75,m), H-
4βABO3(2.06,m), 
MeCHABO3(1.40) 
H-4βABO3(2.06), H-
7xABO3 (2.40), Me 
ABO3(1.40) 
MeCH 1.40 d, J 6.8 17.5 
PhCHABO3(3.48), H-
2αABO3 (2.99,s), H-
4αABO3(2.75) 
PhCHABO3 
(3.48,vw) 
Arom 
7.40-7.28 
7.23-7.18 
(p) 
m 
127.9-
126.1 
(C)142.
9 
  
3
 
Sharp 
 
NH 7.40-7.28     
CO   172.5  
CH
 Ala4 (4.22), 
MeAla4 (1.28), 
OMe(3.62) 
CH 4.31-4.24 m 47.4 MeAla4(1.28,s), NH 
Ala4(7.08) 
COAla4(172.5), 
MeAla4(1.28) 
Me 1.28 d, J  7.2 15.8 CHAla4(4.28,s) COAla4 (4.31) 
NH 7.08 brs  
CHAla4(4.28,s), 
CHAla2(4.24-4.15,vw), 
H-5ABO1(2.58,m), 
H-7ABO1(2.40,w), H-
7ABO1(1.77,vw), 
MeAla4(1.28,s) 
 
4 
OMe 3.63 s 50.8  COAla4(172.5) 
1
 positive NOESY signal cross-peak between the shift of exchanging site. 
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In particular, it is evinced that the signals of two ABO moieties, both in 1H and 13C 
experiments, possess a different shape, one of them is characterized by sharp signals, 
the other by broad signals. These data suggest that one of the ABO scaffold is present 
in different conformations. 
Concerning to the broad signals, our hypothesis is that an electronic repulsion 
between the two basic nitrogen, the nitrogen of the ring and of NH2 of ABO-1, exists 
inducing an equilibrium between the chair-envelope and the boat conformations of  
piperidine ring in the ABO which is reported in the literature having in general a 
chair conformation with the nitrogen substituent in the equatorial position.70  
HMQC experiment allowed to assign unequivocally the chemical shift of the 
carbonyl group of each alanine because a correlation with both CH and Me of each 
corresponding alanine was observed. The carbonyl group of the ABO-3 resonates at 
δ 177.1 and posses a long range correlation with H-7n of ABO-sharp. As a 
consequence the signal at δ 173.2 was assigned to ABO-1. Concerning NH signals, 
COSY and TOXY experiments allowed to assigned unequivocally the correlation 
with the corresponding alanine moiety. Instead, the NHABO-3 is overlapped to the 
aromatic protons. 
The ability of each NH to be involved in an intramolecular hydrogen bond was 
evaluated both at variable temperature and by calculating their exchange rate with 
D2O. 
The exchange process respect a second kinetic order (equation 2) but, considering 
constant the [D2O] concentration (large excess), the system was simplified to a first 
apparent reaction order (equation 4 and 5).  
2)   υ = k [NH] [D2O] 
3)   kapp = k [D2O] 
4)  υ = kapp. [NH] 
5)  -ln([NH]/[NH°] = kapp. [NH] 
 
Here below is reported the graphic representation of the equation 5 for the NH-4 
considering the decreased value of the NH integral against the time (Graphic 1).   
Instead, NH-2 was not detected because the proton was totally exchanged after two 
minutes. 
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Graphic 1a titration data of NH-4 of tetrapeptide 164 
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a[peptide 164] = 14,8 mM in CD3CN (700 µL) then D2O (20 µL), T = 299.94 K 
 
The value of the kapp for NH-4 (3.10-3  s-1M-1) at T = 299.94 K revels a very week 
hydrogen bond interaction, compared to the corresponding value found for the 
corresponding NH-5 in the pentapeptide 156 [kapp for NH-5 (6.10-5  s-1M-1), see 
below]. 
The variation of  NH chemical shift with respect to the variation of the temperature is 
a very useful method to evaluate the  presence of an hydrogen bond and its stability. 
1H NMR spectra of compound 164 in CD3CN were recorded at different temperature 
(from 220 K to 440 K). The δ NH values versus the temperature for NH-4 and NH-2 
(the signals NH-3 and NH2 are overlapped) are reported in Graphic 2. 
By interpolating the experimental values, using the  linear equation y = mx + b, the 
1/m parameter was calculated from which it is evinced that ∆δ/∆T = - 0.85 ppb/K for 
NH-4, and ∆δ/∆T = - 1.20 ppb/K for NH-2.  
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Graphic 2a 
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a
 δNH against the temperature (from 253 K to 337 K) of [peptide 164] = 14,8 mM in 
CD3CN (700 µL). 
 
These data, together with those of hydrogen exchange, are indicative of an 
equilibrium between an intramolecular hydrogen bonded status and a non-hydrogen 
bonded status for NH-4, and that NH-1 is not involved in hydrogen bond. 
Interesting NOE effects were detected which confirm a possible involvement of NH-
4 in a hydrogen bond with CO of ABO-1.  
Furthermore positive Overhauser effects were detected between CHAla2 and NHAla4 
[dα,Ν(i, i+2), vw], which is in general, diagnostic for the presence of a turn which 
confirms spatial proximity between ABO-1 and Ala-4 moieties, and between NHAla4 
and H-7 and H-5 of ABO-1. 
 
The secondary structure of  pentapeptide 156 was deeply studied using NMR 
technique. To achieve the better resolution regarding the proton chemical shifts, 
different solvent were tested (DMSO, CDCl3, CD3CN, CD3OH) and CD3CN was 
then selected. Using NMR analyses (1H, 13C, TOXY, COSY, HSQC, NOESY and 
HMQC, Table 9) we first unequivocally assigned all chemical shifts to each atom as 
well as the sequence of the amino acids. Finally, NMR studies at variable 
temperature as well on the NH-exchange rate were performed.  
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  Figure 41: Noesy peptide 156                                  Figure 42: 3D peptide 156  
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Table 9  the NMR data for the Pentapeptide 156 
Residue atom δ 1H  Multiplicity J (Hz) δ
 13C  Noesy HMBC 
CO   173.6  CH(4.05), Me(1.39) 
CH 4.05 overlapped 51.1 
oArom.
 ABO2 (7.42), 
MeAla1 (1.39), 
PhCHABO-4 (3.65) 
 
Me 1.41-1.37 overlapped 16.4   
NH 6.03 s  
Arom. (7.42),  
CHAla1(4.05,m), 
Me(1.39,s), 
(Me)3C(1.50,w), 
NH
 Ala3(7.49,vw) 
 
Me 1.50 s 26.9 
NHAla3(7.49,w), 
mAromABO2 (7.32), 
oArom
 ABO2(7.42) 
 
C   79.2  Me(1.50) 
1 
Boc 
CO   158.8  CH(4.05), Me(1.39) 
        
CO   175.6 brs   
1 2.17 overlapped 33.1   
2α 2.68 overlapped  
2β 2.37 overlapped 53.7 brs oArom
 ABO2(7.42) 
H-4(2.58), H-
1(2.17) 
4α 2.59 dd, J 8.5, 3.2 
oAromABO2(7.42,m), 
PhCH(3.80,m),     
H-5(2.75,m), H-2 
or/and H-4 (2.37,s), 
Me(1.43,m) 
C-8(36.3), C-
5(39.7), C-2 
(53.5) 
2 broad 
 
 
4β 2.37 overlapped 
51.7 
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5 2.75 brs 39.7 
NHAla5(7.50,vw),   
H-4β(2.37),          
H-4α(2.59) 
H-4(2.58) 
6   64.9 brs   
7x 2.18 overlapped  
7n 1.86-1.78 brs 41.7 brs H-2α (2.65vw), NHAla3(7.49w) 
 
 
8a 1.38 overlapped   
8e 2.18 overlapped 36.3   
PhCH 3.80 brs 62.9 
oArom.ABO2(7.42), 
H-4α(2.59), H-2/H-
4(2.35), Me(1.43) 
 
MeCH 1.43 brs 14.0 brs PhCH (3.80)  
Arom 
7.44-7.40(o) 
7.36-7.28 
(m,p) 
m 
127.6(o)1
26.6(o) 
(CH), 
o140.9(C
) 
7.42 (oArom), 
PhCHABO2(3.80,w), 
H-2 or H-4 or       
H-5(2.69,w),         
H-4αABO2(2.59,w), 
H-2 or                   
H-4ABO2(2.37),      
H-7nABO2(1.77,vw) 
7.42 (ortoArom) 
MeCH(1.43) 
 
 
NH 7.36 overlapped  H-7n(1.77),  H-4α(2.59,w)1  
CO   171.6  CH(4.06), Me(1.42) 
CH 4.06 overlapped 50.3 
Arom. (7.29), 
NHAla5(7.50 vw), 
MeAla3(1.42) 
 
Me 1.42 overlapped 15.4   3 
NH 7.49 scambio 
veloce brs  
MeAla3(1.42), 
CHAla1(4.06,s),  
H-7nABO2(1.86),  
H-5ABO2(2.75,vw), 
NHAla1(6.03,vw) 
 
CO   174.9  
NHAla5(7.50), 
CHAla5(4.22), 
CHAla3(4.06) 
1 2.09 brs 33.1 H-8e(1.15,m) 
H-2(2.18), H-
5(2.65), H-8(2.28, 
1.15); C-6(65.4) 
2α 2.69 overlapped NHABO4(7.55) 
2β 2.18 overlapped 55.9  
H-8(1.15), H-
5(2.65), 
PhCH(3.65) 
4α 2.68 overlapped   
4β 2.06 J 11.0 49.7 
H-8e(1.15), 
PhCH(3.65) 
oAromABO4(7.34) 
 
5 2.65 overlapped 40.2   
6   65.4  H-8(1.15), H-7(2.16), H-4(2.06) 
7x 2.18 overlapped  H-8(1.15) 
7n 2.18 overlapped 40.5   
8a 2.18 overlapped   
4 sharp 
 
8e 1.15 d, J 10.9 36.6 
H-4ß(2.06),  
H-1(2.09),  
H-5(2.65) 
C-1/33.1), C-
7(40.5), C-
4(49.7), C-
2(55.9), C-6(65.4) 
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PhCH 3.65 q, J 7.7 62.9 
oAromABO4(7.34), 
H-4β (2.06), 
HAla1(4.05w), H-2β 
(2.69s), MeCH 
(1.40) 
Arom(7.3), 
Me(1.40), C-
4(49.7), C-
2(55.9), 
MeCH(16.4) 
MeCH 1.41-1.39 overlapped 16.4   
Arom 
7.44-7.40(m) 
7.36-7.28 (o), 
7.27-7.22(p) 
m 
126.0(p)1
28.0-
126.0 
(CH), 
140.8(C) 
mAromABO47.42: 
CHAla3(4.06 w) 
oAromABO47.34: 
PhCHABO4(3.65), H-
4β
 ABO4 2.06),  
 
 
140.8: 
ortoArom(7.34) 
Me(1.39), 
PhCH(3.65) 
 
NH 7.55 brs  CHAla3(4.06s), H-4α(2.68), COAla3(171.6) 
CO   172.6  
CH(4.22), 
Me(1.33), 
OMe(3.62) 
CH 4.25-4.19 m 47.6 NH(7.50), Me(1.33)  
Me 1.33 d, J 7.3 15.8 
NH(7.50), 
CH(4.22), H-5ABO2 
(2.75vw) 
 
NH 7.50 brs  
CHAla5(4.22,s), 
MeAla5(1.33,s), 
CHAla3(4.06,w) 
 
5 
OMe 3.62 s 50.6   
 
As for pentapeptide 164, it is evinced that the signals of two ABO moieties, both in 
1H and 13C experiments, possess a different shape, one of them is characterized by 
sharp signals, assigned to ABO-4 the other by broad signals assigned to ABO-2. 
HMQC experiment allowed to assigned unequivocally the chemical shift of the 
carbonyl group of each alanine because of its correlation with both CH and Me of the 
some alanine moiety. The carbonyl group of the ABO-4 resonates at δ 174.9 and 
possess a long range correlation with NHAla5(δ 7.50), CHAla5(δ 4.22), as well as with 
CHAla3(δ 4.06). Concerning NH signals, COSY and TOXY experiments allowed to 
assigned unequivocally the correlation with the corresponding alanine. Instead, a 
correlation was observed between NHABO4 at δ 7.55 and COAla3 (δ 171.6) which is 
correlated both to CH (δ 4.06) and Me (δ 1.42) of its alanine moiety. As a 
consequence, the chemical shifts at δ 175.6 (brs) was assigned to the carbonyl carbon 
of ABO-2 and at δ 7.36 (overlapped) at NHABO-2. 
The NOESY experiments (only certain significative of non-overlapped signals are 
reported), gave very interesting informations concerning the δ values of ABO 
protons and their spatial relationship. Concerning protons of ABO-4, positive 
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Ovehauser effects were observed between H-4β (δ 2.06)   and H-8e (δ 1.15), and 
between H-4α (δ 2.68) and ΝΗ (δ 7.55), thus assuring the NH assignment for ABO-
4. Instead, no informations are given regarding H-2 since they are overlapped. The 
δ values are tentatively assigned to these protons considering the data available from 
the simple ABO- 3 and the other peptides.33 Concerning ABO-2, NOE effects were 
found between H-7n (δ 1.86-1.78) and H-2α (δ 2.68; this signal is overlapped but it is 
the sole one belonging to ABO-2) and between NH (δ 7.36) and both H-7n and H-
4α (δ 2.59) indicating their cis relationship. Since the two ABO moieties do not have 
spatial proximity (see model), the orto protons of phenyl ring in ABO2 (δ 7.42) 
confirms the above assigned stereochemistry. In fact, NOE effects were observed 
between orto protons and PhCHABO2, H-4αABO2, H-2 or H-4ABO2 (overlapped) and H-
7n
 ABO2 (1.77 vw). Concerning the aromatic region at δ 7.36-7.28, of relevance for 
ABO-4 are the spatial proximity between the signal centered at δ 7.34 (oAromABO4) 
and PhCHABO4 (δ 3.65), and H-4βABO4.  
Concerning the titration, this experiment was performed on pentapeptide 156 (16,8 
mM in CD3CN, 700 µL) in presence of D2O (20 µL). A series of NMR spectra were 
recorded at 299.94 K at different times (from 0 to 5h). No information were given for 
NHABO2 because the signal is overlapped with the aromatic signals but, as evidenced 
in a NOESY experiment of 156 in CD3CN/D2O, it easily exchange with D2O. 
Furthermore, the kinetic exchanges of NH-3 its so fast that the signal was lost in few 
minute. Concerning NHBoc, NH-4 and NH-5, integral values were reported in the 
graphic below (Graphic 3). 
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Graphic 3. Plot of the variation of NH integrals in the 1H NMR spectra of 156 vs. 
time.a 
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a[peptide 156] = 16,8 mM in CD3CN (700 µL) then D2O (20 µL), T = 299.94 K 
 
From these data it is clear that the NH-5 is involved in a very slow exchange process. 
In fact, after a 8h, the NH integration area was reduced of about 20%. NH-4 slowly 
exchange too, but the integration area was reduced of 80% after 8h. Concerning NH-
1 of carbamate, even if a comparable kinetic with the other signals is not possible 
because this proton is different with respect to the others NH, it was found that its 
deuteration is very fast.  
Here below is reported the graphic representation of the pentapeptide 156 titration 
considering the decreased value of the NH integrals against the time  (graphic 4). 
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Graphic 4: Plot of the variation of  –ln(NH/NH°)  of compound 156 vs. time.a 
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a[peptide 156] = 16,8 mM in CD3CN (700 µL) then D2O (20 µL), T = 299.94 K 
 
Using Equation 5 it is possible to calculate the kapp for NH-4 (4.10-4  s-1M-1)  NH-5 
(6.10-5  s-1M-1)  and NH-1 (4.10-3 s-1M-1). This means that NH-1 exchanges 10 time 
faster than NH-4, and NH-4 exchanges 10 time quicker that NH-5 at T = 299.94 K. 
(Graphic 4).The variation of  NH chemical shift with respect to the variation of the 
temperature is also performed. 1H NMR spectra of compound 156 in CD3CN were 
recorded at different temperature (from 212.04 K to 348.33 K) and the results of 
these experiments confirm the data deduced from titration experiments.The δ NH 
values versus the temperature for all NH, except for NH-2 (overlapped with aromatic 
hydrogens), are reported in Graphic 5. The plot in Graphic 6 represents the expanded 
area of NH chemical shifts (from 7.40 to 7.90 ppm) versus temperature (from 212.51 
K to 314.57 K). 
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Graphic 5: NH chemical shift against temperaturea 
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 δNH against the temperature (from 212.04 K to 348.33 K) of [peptide 156] = 16,8 
mM in CD3CN (700 µL) 
 
Graphic 6: expansion of the graphic 5a  
 
a 
δNH against the temperature(from 212.51 K to 314.57 K) of [peptide 156] = 16,8 
mM in CD3CN (700 µL). 
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As you can see the linearity was not maintained in the large range of temperature 
analyzed (from 212.04 K to 348.33 K). Only in the 271.51 K to 314.57 K range 
(expansion in graphic 6) a linear relationship between the NH shift and the 
temperature was observed. When the temperature is higher, probably, a 
“denaturation” process is involved and the peptidic secondary structure change. 
Instead, at lower temperature we observed the formation of other hydrogen bonds 
that again could change the secondary structure.  
The above data were reported here below in the histogram of ∆δNH/∆T in which is 
evident the low δ variation for NH-4 and NH-5. (Graphic 7) 
 
Graphic 7 variations of the NH proton chemical shifts for peptide 156 toward the 
temperature.a 
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a
 ∆δNH/∆T considering the linearity ∆T (271.51 K to 314.57 K) range values.   
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In Table 5 are resumed all the data for the pentapeptide 156. 
 
Table 5 reports on the resumes data 
 
 
 
 
 
 
 
 
[a] Complete proton resonance assignments were made with the aid of COSY experiments;  
[a] δ value determined to T° = 299,93(K); 
[b]
 (∆δNH/∆T) coefficients  were determined between 271 and 314(K) (were a linear dependence of 
all signals was observed) and  [peptide 156]= 16,8 mM in CD3CN;  
[c]
 N-H/N-D exchange rate [peptide 156]= 16,8 mM in CD3CN (700 µL) D2O (20 µL)T° = 
299,93(K);  
[d]
 Not determined because overlapped with other resonances; 
[e] Not determined because the excange is too fast;  
 
From these data appears that the amide protons NH-5 and NH-4 are in an 
intermolecular hydrogen-bonded status. As reported in Table 5, the temperature 
dependence of the NH-5 chemical shifts falls within the typical values for 
intramolecularly hydrogen bonded protons. A slightly higher is observed for NH-4 
instead, amide protons NH-1 and NH-3 exhibit a larger temperature dependence as 
well as a quick deuterium exchange with respect to the other amide protons. 
Furthermore, the good linearity of the chemical shift vs. temperature (271.51 K to 
314.57) of NH-4 and NH-5 indicates the absence of conformational changes over the 
temperature range swept.71 Our hypothesis is that NH of ABO-4 is involved in a 
medium hydrogen bond with the carbonyl group of Ala-1 and that a strong hydrogen 
bond was effective between NH Ala-5 and the carbonyl group of ABO-2. Since COi-
NHi+3 hydrogen bond are typical of a 310-helix, this secondary structure was assigned 
to pentapeptide 156.72  This hypothesis was supported by NOESY experiments 
6*10-5 -2.23 7.52 H5 
4*10-4 -3.74 7.55 H4 
-
[e]
 -4.76 7.47 H3 
-
[d]
 -
[d]
 7.42 H2 
4*10-3 -8.27 6.03 H1 
kapp(1/s) exchange reaction 
with D2O[c] 
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(ppb/K)[b] 
δ 
(ppm)[a] 
N-H 
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which were performed on a sample of  156 dissolved both in CD3CN and in 
CD3CN/D2O (in this case we ensured the NOE effects for NHAla5 since the other NH 
disappeared). Interesting informations are given regarding to the secondary structure. 
Of relevance are the NOESY effects between the NHAla3 (δ 7.49) with NHBoc group 
(both with Me and NH [dN,N(i, i+2), w]. Positive Overhauser effects were observed 
between the H-7n of ABO-2 with  NHAla3 [dβ,N(i,i+1), w] and between H-5 with 
both NH
 Ala5 [dβ,N(i,i+3), vw] and  MeAla5 (vw). Other NOE contacts of relevance are 
those of NHABO4 and  CHAla3 [dα,N(i,i+1, s], and between this last and  NH Ala5 
[dα,Ν(i, i+2, vw]. The proposed secondary structure is also consisted  with the spatial 
proximity observed  between CHAla3 (δ 4.06) and  the signals δ at 7.42 (w) and at δ 
7.34 assigned to H-metaABO4 and H-ortoABO4, respectively. 
Figure 43 Summary of the NOEs-derived backbone obtained for peptide 156 in 
CD3CNa 
 
a Peaks are grouped into three classes based upon their integrated volume 
As reported above, differently to the signals of ABO-2, ABO-4 shows broad signals 
suggesting that more than one conformation is possible for the nitrogen ring in this 
scaffold. This result is comfirmed by the peptide molecular model in which it is 
evinced that when the benzyl group of ABO-4 is located in the equatorial position it 
is more crowded with respect to its location in the axial position.  
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4    Metallorganic ligands  
 
4.1  ABO as a metal ligand   
 
As reported in the introduction, a promising research field is the bio-organometallic 
chemistry.  In fact small peptidomimetics containing a metal center can be 
considered synthetic enzyme analogues.73 In this view we have  tested compounds 
ABO (exo)-(-) 124’ and ABO (exo)-(±) 122a  as ligands into transition metal 
complexes (figure 44). Furthermore, we studied also a new organometallic ligand 
characterized by norbornene structure.74 (See figure 45) 
This part of my researches was developed under the supervision of Professor Oliver 
Reiser of the University of Regensburg (Germany) who introduced me into the 
“World” of metallo-organic chemistry.  
 
Figure 44 
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ABOs attract our interest because they are polifunctional compounds, with different 
possible points of interaction with a metal, i.e. the amino,  amido  and phenyl  groups 
which can be conveniently used to stabilize the metal-ligand interactions. Nitrogen 
compounds are highly attractive as ligands for transition-metal complexes, and their 
application in catalysis become one of the major research topic.75 Amines in fact do 
not suffer from the intrinsic drawbacks of phosphanes, such as their oxygen 
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sensitivity. Moreover the biological systems are rich of chiral nitrogen compounds. 
However late-transition–metal amine complexes are often not very stable and the 
amine is rather easily displaced by a σ donor. Complexes with sp2 valence electron 
configured nitrogen donors seem to have a higher stability.76  
Preliminary considerations  about ABOs take into account the hard/soft character of 
the binding site. Particularly, the N atoms present in these molecules possess 
different features and an hard-borderline character; furthermore, the phenyl group 
can operate in the complex formation too.77 As reported in the sperimental section by 
the spectroscopic data (1H NMR, 13C NMR, COSY, NOESY; Hector) a predominant 
chair-envelope conformation for 3-azabicyclo[3.2.1]octane is proposed.  
Geometrical consideration revealed that the N amine and the N amidic lone pairs 
pointed in a convenient direction and computational studies analyzed the distance 
between this two groups.  
All these informations have been used to focalize our studies into a small number of 
transition metals. Our first choice was directed toward borderline metals 
characterized by square planar geometry such as Cu2+, Zn2+, Ni2+ Pd2+, Ru+1 and 
Co2+. Different reaction conditions i.e. temperature ( 25°C , 40°C, 70°C) and solvents 
(CH2Cl2, and MeOH or EtOH) were evaluated (see table 14).78 In order to archived 
the formation of the complex both starting from 124’ and 122a  
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Scheme 28 
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Table 14 reagents and conditions  
ligand metal salt 
Ratio 
Ligand/metal 
 
solvent T°C time (s) 
122a ABO (±) NiCl2*6H2O 2:1 EtOH 60 and 25 24 
122a ABO (±) Cu(ClO4)2*6H2O 2:1 EtOH 60 and 25 24 
122a ABO (±) CoCl2*6H2O 2:1 EtOH 60 and 25 24 
122a ABO (±) ZnCl2 2:1 EtOH 60 and 25 24 
122a ABO (±) MnCl2 2:1 EtOH 60 and 25 24 
122a ABO (±) FeCl2*4H2O 2:1 EtOH 60 and 25 24 
124’ ABO exo (-) Cu(ClO4)2*6H2O 2:1 EtOH 60 and 25 24 
124’ ABO exo (-) Pd(OAc)2 2:1 EtOH 60 and 25 24 
124’ ABO exo (-) NiCl2 2:1 EtOH 60 and 25 24 
124’ ABO exo (-) CuCl2*2H2O 2:1 CH2Cl2 25 24 
124’ ABO exo (-) [Ru(p-Cymene)Cl]2 2:1 CH2Cl2 25 24 
124’ ABO exo (-) [Ru(p-Cymene)Cl]2 2:1 CH2Cl2 Reflux 24 
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The solvent was removed and the row reaction mixture was analyzed by different 
techniques, i.e. NMR, IR, and MASS (ESI) spectroscopy.   
Our explorative researches did not give the expected results,  ABO  scaffold was not  
useful as a ligand for a stable metal complex.  
Our failure could be caused  by the rigidity of the ligand structure that increase the 
transition state energy in the formation of the metal complex, or also by a steric 
hindrance of the ligand can interfered in the chelation process.   
Another possibility could be the not optimal overlapping  of the metal  and ligand 
orbitals and,  consequently, a week interaction which makes instable the M-L 
complex, more sensitive to the solvent and temperature effects.  
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4.2 norborne oxazoline ligands 
 
In the second part of my experience I changed the ligand and I studied a new class of 
bidentate ligand containing both Hard and Soft binding sites, these molecules are 
characterized by a double bond (Soft) and a nitrogen (Hard) binding sites. The 
interest toward this class of compounds is related to the scarce literature data 
regarding complexes with molecules having both Hard/Soft binding sites. 
Furthermore they are considered very instable complexes.  
 
Figure 45  
165
H2N
HN
SO
N O
O
Me
166 167
 
 
First we have synthesized a series of compounds 165, 166 and 167 as shown in 
figure 45. 
These three compounds present a different nitrogen atom characterized by different 
hardness. In compound 165, the nitrogen can be considered an hard sp3 weak σ-
donor, in compound 166 the nitrogen atom has a more soft character because its lone 
pare delocalizes in the sufamidic function, and  in the oxazoline derivative 167 the 
nitrogen atom was characterized by a hard sp2 good σ-donor. Furthermore, the 
phenyl group in compounds 166 and 167 can interact with the metal  improving the 
stabilization of the metal complex.  
I developed two different synthetic strategies to access in few steps to these 
compounds. 
The first synthetic strategy is reported in the scheme 29  and consists in the Diels-
Alder reaction between acrylonitrile 168 and cyclopentadiene 48 which operating in 
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CH2Cl2 using Mg(ClO4)2 as the catalyst and ultrasound. A mixture of cycloadducts 
169b-exo and 169a-end  were obtained which can be easy separated by column 
chromatography. Only the major endo racemic compound was useful for our further 
studies. The reduction of the nitrile function using LiAlH4 in diethyl ether to the 
corresponding amine gave compound  165. Compound 165 was then transformed 
into the corresponding tosylamide 166 by reaction with TsCl.  
 
 
Scheme 29  
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In order to obtain compound 167, we have developed a different synthetic strategy 
(Scheme 30). First we prepared the oxazoline compound 174 and then by a Diels-
Alder reaction with cyclopentadiene it is possible to obtain a mixture of compounds 
175a and 175b easily separed by column cromatography. Also in this case, the endo 
compound is of our interest.  
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Studies on the formation of the complexes was performed using different kind of 
solvents and metals as reported in the table below.  
 
Table 15  
ligand metal salt Ratio Ligand/metal 
 
solvent T°C time (s) 
167 Cu(AcO)2 2:1 EtOH 60 and 25 24 
167 [RhCl(COD)]2 2:1 EtOH 60 and 25 24 
165 [Ru(p-Cymene)Cl]2 2:1 THF RT 16 
166 [Ru(p-Cymene)Cl]2 2:1 THF RT 16 
165 RuCl3 2:1 CH2Cl2 25 24 
165 [Ru(p-Cymene)Cl]2 2:1 MeOH 25 24 
166 [Ru(p-Cymene)Cl]2 2:1 CH2Cl2 Refluxed 24 
 
All reactions mixture ( see table 15) were analyzed by MASS techniques which is 
diagnostic for the formation of the complex.  Only using NOXA ligand 175a 
(Norbornene OXAzoline compounds) and Rh+1 as a metal  was observed the 
formation of a complex. Furthermore, 1H NMR analysis confirmed the ligand 
chelation,  since a significant shift of the oxazoline signals (δ 1H and δ 13C) was 
observed. Instead, the interaction between the metal and the double bond was not 
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observed (no significant shift of the double bond signals). Our hypothesis is that 
complex  176 reported below could be formed.  
 
Figure 46 
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Further studies are in progress modifying the ligand structure 175a in order to obtain 
an optimal distance and a favorable geometry between the two function (nitrogen and 
the double bond), aiming to synthesized a bidentate ligand. Also further transition 
metal, with a different hardness and geometry,  have to be evaluated.    
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5 ABO in Organocatalysis   
 
5.1 Introduction  
 
The use of ABO as an organocatalyst was performed in collaboration with Prof.ssa 
Clerici and Prof.ssa La Rosa of the University of Milano, and was a part of a large 
ongoing program in which the study of Diels-Alder and Staudinger reactions were 
one of the main research field. Our compounds together with other amine derivatives 
were tested in the above reactions. 
 
The presence of an amine in the azabicyclo[3.2.1]octane ring makes ABO an 
interesting tool in organo catalyst-mediate  asymmetric reactions. In the literature 
there are a huge numbers of reaction catalyzed by a small rigid molecule, in which, 
the secondary amine function is the active site responsible of the substrate activation. 
Furthermore, these catalysts tagged the reagents in a particular spatial position 
inducing a particular stereochemistry on the product. Since  ABO derivatives are 
rigid molecules available in enantiopure form too, they are interesting and potential 
organocatalyst. 
 
Figure N 
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5.2  Studies on Diels-Alder reaction  
 
The catalytic cycle of amino organo-catalyzed Diels-Alder reactions is reported 
below. The condensation of the amine 181 with an aldehyde 177 leads to the 
formation of an iminium ion  (step 1) that is sufficiently activated to engage a diene 
reaction partner79 with cyclopentadiene (step 2). The hydrolysis of compound 179 
allows to obtain the product and to regenerate the free catalyst for the next catalytic 
cycle (step 3) . 
 
Scheme  31  Diels-Alder catalytic circle  
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It is  well known, that in general, secondary amines are requested to improve 
significantly the yield. In a preliminary study we planned  to test the racemic mixture 
of both exo-ABO and endo-ABO. 
The ability of our amines to catalyze the Diels-Alder reaction was tested in the 
reaction of  cypentadiene 48 and an α,β-insatured-aldehyde (E-cynnamaldehyde 182) 
as a dienophile. Which do not work without the catalyst 80. 
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The reaction was performed in a screw-cap-tube in which the adehyde 182 (1 eq) was  
dissolved in MeCN/H2O (95:5)  with ABO catalyst (128). The cyclopentadiene 48 (3 
eq. in MeCN) was added and the reaction was sonicated for 42 h. The cycloddition 
products were isolated by chromatography and analyzed by HPLC to evaluate the 
enantiomerically excess.  
 
Scheme 32 
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In principle four stereoisomers could be formed: a couple of endo enantiomers 183 
and 183’, and a couple of exo 184 and 184’. But this reaction do not work without 
catalyst.  
 
Table 16  results and conditions of Diels-Alder reaction  
 
Dienophile 
eq. 
Diene 
Eq. Catalyst Solvent Time 
Temperature 
Condition 
exo:endo 
ratio yield 
1 3 
10% mol
NH
MeOOC
MeOCHN
HCl
128
 
CH3CN/H2O 
95/5 42h Ultrasound 1:1 
18 
% 
1 3 
15% mol
NH
MeOOC
MeOCHN
HCl
128
 
CH3CN/H2O 
95/5 72h ultrasound 1:1 
28 
% 
1 3 
10% mol
NH
MeOOC
MeOCHN
HCl
128
 
CH3CN/H2O 
95/5 42h ultrasound 1:1 
28 
% 
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The results shown in Table 16 evinced that the reaction yields are modest improved 
compared to the simple acid catalysis reaction (10 %)81 but are lower compared to 
other organo-catalyst such as McMillan catalyst (0-94%)82 or proline derivatives (10-
86%)81. Concerning the exo:endo ratio, we don’t have significant results which is an 
analogues ratio found by Mc Millan82. 
 
5.3   Staudinger reaction. 
 
Concerning the Staudinger reaction, ketene 185 was made to react with the imine 186 
to generate a β-lactam derivatives 187.  
 
Scheme 33  
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The catalytic cycle for the above Staudinger like reaction is reported below. First, 
ketene N reacts with a catalytic tertiary amine (step 1) forming the active 
intermediate N which gives a nucleophilic attack on the electron poor imine N  (step 
2). Finally, compound N was formed by cyclization (step 3). Recent result 
demonstrate83 that a chiral nucleophilic base could dramatically enhance the rate and 
the yields in the formation of β-lactam derivatives obtained a good 
diastereoselectivity and enantioselectivity for analogue reaction. 
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Scheme 34  
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In our case we studied the reaction of ketene 193 with imine 194 racemic ABO 123a 
and enantiopure compound (+)-125 were tested as catalysts. To generate the ketene 
193 tioazolidinic acid 190 (2 eq.) reacted in the presence of the Mukayama activator 
191 (2.31 eq.) and a non nucleophylic base protonsponge 192 (2 eq.). This reaction 
was perfomed in toluene at 70°C. In the second step the electron poor imine 194 (1 
eq.) and the tertiary catalytic base ( ABO 123a or (+)-125:  0.1 eq.) and a further 
amount of a protonsponge base 192 (4 eq.) were added and mixture of 
diastereoisomeric compounds 195 β1, 195 β2 was formed. 
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Scheme 35  
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Table 17 
 
Base catalyst T, °C 
Ratio 
Acid:imine 
yield 
de 
β1 : β2 
e e 
β1 
1 
(±)-ABO 
123a 
70 1 : 1 1.5 // // 
2 
(±)-ABO 
123a 
70 2 : 1 12.3 75 : 25 // 
3 (+)-ABO 125 r.t 2 : 1 4.8 86 : 14 0 
4 (+)-ABO 125 70 2 : 1 14.1 71 : 29 0 
 
The results evinced that the reaction does not work very well. In particular yields are 
very low probably because the steric hindrance of the reactants make difficult the 
cyclization (catalytic cycle, step 3). 
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6. Experimental Section 
 
Compounds exo-111a, endo-112a, exo-111b and endo-112b were prepared according 
to a know procedure. 
General Procedure for the Synthesis of Diols 118, 119. Compound 111, 112 
[exo-111a or endo-112a or a mixture of exo-111a/endo-112a (7 : 3) (209 mg, 1 
mmol); exo-111b or endo-112b (409.6 mg, 1 mmol)] was suspended in a mixture of 
acetone/H2O (6 mL, 10 : 1). After addition of N-methylmorpholine-N-oxide (176 mg, 
1.5 mmol) and OsO4 (1.35 mg, 0.005 mmol) the solution turned brown. The reaction 
mixture was stirred at room temperature for 8 h after which the solvent was 
evaporated. The crude reaction mixture was filtered on silica gel (CH2Cl2/MeOH = 5 
: 1).
 
Pure compound 118, 119 (exo-118a: 209 mg, 86 %; endo-119a: 204 mg, 84 %; 
exo-118a/endo-119a: 202 mg, 83 %) was obtained after crystallization. The crude 
reaction mixture containing 2b was taken up with a saturated solution of Na2S2O4 (5 
mL) and extracted with CH2Cl2 (3 x 5 mL). After drying of the organic layer with 
Na2SO4 and column chromatography on silica gel (CH2Cl2/MeOH = 20 : 1) pure 
compound 118b, 119b (exo-118b: 404 mg, 90%; endo-119b: 430 mg, 97%) was 
isolated.  
Methyl  (1R*, 2S*, 4S*, 5S*, 6R*)-2-Acetylamino-5,6-
dihydroxybicyclo[2.2.1]heptane-2-carboxylate exo-118a. Mp 161 °C 
(MeOH/iPr2O); IR νmax 3500-3100, 1735, 1651 cm-1; 1H NMR (CD3OD) δ 3.97  (d, J 
= 6.2, 1 H), 3.73  (d, J = 5.0, 1 H), 3.67 (s, 3 H), 2.71 (bs, 1 H), 2.22 (dd, J = 13.8, 
5.0, 1 H), 2.09 (bs, 1 H), 1.94 (s, 3 H), 1.94-1.91 (m, 1 H), 1.64 (d, J = 10.9, 1 H), 
1.34 (dd, J = 13.8, 2.9, 1 H); 13C NMR (CD3OD) δ 174.6, 172.9, 73.9, 69.3, 62.6, 
51.8, 50.4, 43.3, 38.3, 31.3, 21.0; m/z 244.2 [M+]; Anal. Calcd for C11H17NO5: C, 
54.31; H, 7.04; N, 5.76. Found: C, 54.28; H, 7.10; N, 5.68. 
Methyl  (1S*, 2S*, 4R*, 5R*, 6S*)-2-Acetylamino-5,6-
dihydroxybicyclo[2.2.1]heptane-2-carboxylate endo-119a. Mp 186 °C 
(MeOH/iPr2O); IR νmax 3346, 1731, 1694 cm-1; 1H NMR (CD3OD) δ 3.74  (dd, J = 
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6.2, 1.4, 1 H), 3.66 (s, 3 H), 3.57 (dd, J = 5.8, 1.4, 1 H), 2.38 (dd, J = 13.9, 2.5, 1 H), 
2.23 (bs, 1 H), 2.16-2.14 (m, 1 H), 1.97 (dt, J = 10.6, 1.1, 1 H), 1.88 (s, 3 H), 1.65 
(dt, J = 10.6, 1.5, 1 H), 1.54 (ddd, J = 14.0, 5.1, 0.7, 1 H); 13C NMR (CD3OD) δ 
173.1, 171.5, 72.8, 68.9, 63.8, 52.3, 51.6, 43.9, 38.8, 31.8, 20.8; m/z 244.2 [M+]; 
Anal. Calcd for C11H17NO5: C, 54.31; H, 7.04; N, 5.76. Found: C, 54.25; H, 7.12; N, 
5.67. 
(-)-8-Phenylmenthyl (1R, 2S, 4S, 5S, 6R)-2-Acetylamino-5,6-
dihydroxybicyclo[2.2.1]heptane-2-carboxylate exo-118b. Mp 235 °C (CH2Cl2/i-
Pr2O); [α]D25 = -9.1° (c 0.5, MeOH); IR νmax 3360-3300, 1715, 1647 cm-1; 1H NMR 
(CD3OD) δ 7.34-7.11 (m, 5 H), 4.83-4.71 (m, 1 H), 3.97 (d, J = 6.2, 1 H), 3.66  (d, J 
= 5.5, 1 H), 2.61 (bs, 1 H), 2.26 (dd, J = 13.9, 5.1, 1 H), 2.05-1.77 (m, 3 H), 1.90 (s, 3 
H), 1.55-0.72 (m, 9 H), 1.35 (s, 3 H), 1.24 (s, 3 H), 0.86 (d, J = 6.6, 3 H); 13C NMR 
(CD3OD) δ 172.9, 171.6, 153.3, 128.5, 125.9, 124.9, 77.4, 73.8, 69.3, 62.6, 50.8, 
50.2, 43.7, 40.9, 39.7, 38.1, 35.0, 31.5, 29.9, 29.6, 26.8, 24.1, 23.5, 21.9; m/z 466.4 
[+Na]; Anal. Calcd for C26H37NO5: C, 70.40; H, 8.41; N, 3.16. Found: C, 70.33; H, 
8.45; N, 3.10. 
(-)-8-Phenylmenthyl (1S, 2S, 4R, 5R, 6S)-2-Acetylamino-5,6-
dihydroxybicyclo[2.2.1]heptane-2-carboxylate endo-119b. 249 °C; [α]D25 = +13 (c 
0.5, MeOH);  IR νmax 3375, 1704, 1649 cm-1; 1 H NMR (CDCl3) δ 7.40-7.16 (m, 5 H), 
5.00 (s, 1 H, exch.), 4.69-4.59 (m, 1 H), 3.90 (d, J = 5.9, 1 H), 3.82 (d, J = 6.3, 1 H), 
2.22-2.00 (m, 3 H), 2.00-1.80 (m, 4 H), 1.81 (s, 3 H), 1.79-1.42 (m, 4 H), 1.34 (s, 3 
H), 1.30-0.80 (m, 2 H), 1.17 (s, 3 H), 0.87 (d, J = 6.7, 3 H); 13C NMR (CDCl3) δ 
171.8, 169.9, 152.9, 128.4, 125.9, 125.1, 77.7, 73.2, 69.4, 63.7, 52.3, 49.8, 44.4, 41.0, 
39.8, 39.2, 35.0, 32.5, 31.6, 28.9, 27.0, 25.1, 23.3, 22.0; m/z 466.4 [+Na]; Anal. 
Calcd for C26H37NO5: C, 70.40; H, 8.41; N, 3.16. Found: C, 70.47; H, 8.39; N, 3.13. 
General Procedure for the Preparation of bis-Aldehydes 120, 121. Compound 118, 
119 (118a: 243 mg, 1 mmol; 119b: 443 mg, 1 mmol) was dissolved in a mixture of 
dioxane/H2O (5 mL, 8 : 1). NaIO4 was added (1.7 g, 7.92 mmol) and the mixture was 
stirred at room temperature for 2 h. The solvent was evaporated and the reaction 
mixture was taken up with CHCl3 (10 mL) and the salts were filtered and washed with 
CHCl3. The organic solution was collected and, after solvent elimination, the crude 
aldehydes 120 or 121 [exo/endo-118a/119a: 120a, 121a (240 mg); exo-118a: 120a 
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(232 mg); endo-119a: 121a (234 mg); exo-118b: 120b (395 mg), endo-119b: 121b 
(398 mg)] were isolated and used without further purification.     
Methyl (1S*, 2R*, 4S*)-1-Acetylamino-2,4-diformyl-cyclopentanecarboxylate 
120a: crude compound.  IR νmax 3346, 1731, 1694 cm-1; 1 H NMR (CDCl3) δ 9.76 (s, 1 
H), 9.71 (s, 1 H), 6.50 (s,  H, exch.), 3.77 (s, 3 H), 3.25-3.05 (m, 1 H), 2.50 (dd, J = 
13.9, 3.7, 1 H), 2.40-1.90 (m, 4 H), 1.91 (s, 3 H); 13C NMR δ 202.7, 172.0, 170.8, 
66.6, 57.2, 53.3, 47.4, 37.0, 24.7, 22.9; m/z 242.1 [M+].      
Methyl (1S*, 2S*, 4R*)-1-Acetylamino-2,4-diformyl-cyclopentanecarboxylate 
121a: crude compound.   IR νmax 3391, 1728, 1658 cm-1; 1H NMR (CDCl3) δ 9.68 (s, 1 
H), 9.67 (s, 1 H), 6.70 (s, H, exch.), 3.69 (s, 3 H), 3.20-2.90 (m, 1 H), 2.60-1.90 (m, 4 
H), 2.01 (s, 3 H); 13C NMR δ 201.7, 200.0, 173.0, 170.5, 65.7, 58.4, 53.2, 48.9, 36.8, 
27.2, 23.9; m/z 242.1 [M+].       
(-)-8-Phenylmenthyl (1S, 2R, 4S)-1-Acetylamino-2,4-diformyl-
cyclopentanecarboxylate 120b: crude compound. IR νmax 3428, 1759, 1633 cm-1; 
1H NMR (CDCl3) δ 9.73 (s, 1 H), 9.48 (d, J = 0.81, H), 7.39-7.11 (m, 5 H), 6.35 (s, 1 
H, exch.), 4.93-4.88 (m, 1 H), 3.02-2.92 (m, 1 H), 2.40-2.31 (m, 1 H), 2.25 (dd, J = 
14.0, 2.3, 1 H), 2.20-2.13 (m, 1 H), 2.12-1.75 (m, 5 H), 1.84 (s, 3 H), 1.68 (dd, J = 
14.0, 10.1, 1 H), 1.60-1.50 (m, 1 H), 1.32 (s, 3 H), 1.28-1.18 (m, 1 H), 1.14 (s, 3 H), 
1.10-0.97 (m, 2 H), 0.93 (d, J = 6.6, 3 H); 13C NMR (CDCl3) δ 202.2, 197.3, 169.6, 
168.8, 152.1, 127.4, 124.9, 124.3, 76.6, 65.5, 55.9, 48.5, 45.3, 40.1, 38.7, 35.0, 34.0, 
30.7, 30.3, 25.8, 23.3, 21.7, 21.1, 20.8; m/z 442.5 [M+].
 
(-)-8-Phenylmenthyl (1S, 2S, 4R)-1-Acetylamino-2,4-diformyl-
cyclopentanecarboxylate 121b: crude compound. IR νmax 3390, 1727, 1651 cm-1; 
1H NMR (CDCl3) δ 9.69 (d, J = 1.5, 1 H), 9.61 (d, J = 1.3, 1 H), 7.32-7.15 (m, 5 H), 
6.05 (s, 1 H, exch.), 5.04-4.95 (m, 1 H), 3.27-3.12 (m, 1 H), 2.43 (dd, J = 14.0, 10.0, 
1 H), 2.33 (dd, J = 9.3, 9.2, 1 H), 2.12-1.95 (m, 2 H), 1.97 (s, 3 H), 1.90-1.80 (m, 2 
H), 1.72-1.55 (m, 3 H), 1.50-1.40 (m, 1 H), 1.36 (s, 3 H), 1.22 (s, 3 H), 1.18-0.80 (m, 
3 H), 0.90 (d, J = 6.5, 3 H); 13C NMR (CDCl3) δ 202.0, 200.1, 171.5, 170.3, 151.7, 
128.7, 125.9, 78.8, 67.1, 57.9, 50.3, 48.9, 41.8, 40.3, 35.6, 34.6, 31.8, 27.7, 27.3, 
27.0, 26.5, 24.5, 22.1; m/z 442.5  [M+].   
General Procedure for the Reductive Amination: Synthesis of 3-Aza-
bicyclo[3.2.1]octane Derivatives 122/123 a,b. Aldehyde [120a/121a (242 mg, 1 
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mmol); 120b/121b (442 mg, 1 mmol)] was dissolved in anhydrous dichloroethane (4 
mL) under nitrogen. Operating under stirring at room temperature, p-
methoxybenzylamine (137.2 mg, 1 mmol), NaBH(OAc)3 (487.0 mg, 2.3 mmol) and a 
catalytic amount of AcOH were added. After 4 h,  the solvent was evaporated and the 
crude reaction mixture was taken up with CH2Cl2 (5 mL). The organic layer was 
washed with H2O (5 mL) and dried over MgSO4. The crude reaction was 
chromatographed on silica gel (122a: CH2Cl2/MeOH = 20 : 1; 123b: CH2Cl2/MeOH 
= 50 : 1) giving pure 3-aza-bicyclo[3.2.1]octane derivatives 122/123 after 
crystallization [120a: exo-122a (211 mg, 61%); 121a: endo-123a (183 mg, 53%); 
120a/121a: exo-122a (141 mg, 41%), endo-123a (52 mg, 15%); 120b: exo-122b 
(311 mg, 57%); 121b: endo-123b (317 mg, 58%)] . 
Methyl (1S*, 5S*, 6S*)-6-(Acetylamino)-3-(4-methoxybenzyl)-3-
azabicyclo[3.2.1]octane-6-carboxylate exo-122a. Mp 143-145 °C (benzene); IR 
νmax 3344, 1737, 1637 cm-1; 1H NMR (CDCl3) δ 7.16, 6.84 (AA'XX' system, J = 8.4, 
4 H), 6.44 (s, 1H, exch.), 3.78 (s, 3 H), 3.67 (s, 3 H), 3.55, 3.17 (AB system, J = 
12.5, 2 H), 2.83-2.75 (m, 1 H), 2.72 (brs, 1 H), 2.56-2.50 (m, 1 H), 2.40-2.30 (m, 2 
H), 2.20 (bs, 1 H), 2.03-1.98 (m, 2 H), 1.72 (dd, J = 13.5, 2.5, 1 H), 1.57 (s, 3 H), 
1.50 (dd, J = 11.1, 2.5, 1 H); 13C NMR (CDCl3) δ 174.4, 171.0, 159.2, 130.6, 130.6, 
114.2, 65.9, 62.2, 61.0, 55.6, 54.9, 52.5, 43.0, 40.0, 37.1, 34.7, 22.5; m/z 347.3 [M+]; 
Anal. Calcd for C19H26N2O4: C, 65.87; H, 7.56; N, 8.09; Found: C, 65.85; H, 7.55; N, 
8.06.     
Methyl (1R*, 5R*, 6S*)-6-(Acetylamino)-3-(4-methoxybenzyl)-3-
azabicyclo[3.2.1]octane-6-carboxylate endo-123a. Mp 155-157 °C (benzene); IR 
νmax 3265, 1747, 1640 cm-1; 1 H NMR (CDCl3) δ 7.23, 6.84 ( AA'XX' system, J = 
8.5, 4 H), 5.72 (s,  H, exch.), 3.80 (s, 3 H), 3.69 (s, 3 H), 3.42, 3.33 (AB system, J = 
13.0, 2 H), 3.01 (dd, J = 13.9, 1.8, 1 H), 2.84 (d, J = 10.2, 1 H), 2.71 (d, J = 8.4, 1 H),  
2.30 (bs, 1 H), 2.30-1.85 (m, 5 H), 1.96 (s, 3 H), 1.51 (dd, J = 11.3, 2.2, 1 H); 13C 
NMR (CDCl3) δ 172.5, 169.7, 159.0, 131.1, 130.4, 113.9, 68.5, 62.0, 59.0, 55.9, 
55.6, 52.5, 46.8, 39.9, 37.1, 35.1, 23.7; m/z 347.3 [M+]; Anal. Calcd for C19H26N2O4: 
C, 65.87; H, 7.56; N, 8.09. Found: C, 65.91; H, 7.54; N, 8.08. 
(-)-Phenylmenthyl (1S, 5S, 6S)-6-(Acetylamino)-3-(4-methoxybenzyl)-3-
azabicyclo[3.2.1]octane-6-carboxylate exo-122b. Mp 186 °C (i-Pr2O); [α]D25 = -
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46.5° (c 5.24, CHCl3); IR νmax 3400, 1730, 1657 cm-1; 1 H NMR (CDCl3) δ 7.28-7.08 
(m, 6 H), 7.08-6.98 (m, 1 H), 6.86 (d, J = 8.4, 2 H), 5.94 (s, 1 H, exch.), 4.81-4.65 
(m, 1 H), 3.80 (s, 3 H), 3.54, 3.16 (AB system, J = 12.5, 2 H), 2.90-2.70 (m, 1 H), 
2.65-2.00 (m, 4 H), 2.00-1.80 (m, 2 H), 1.60-0.70 (m, 11 H), 1.58 (s, 3 H), 1.30 (s, 3 
H), 1.19 (s, 3 H), 0.83 (d, J = 6.2, 3 H); 13C NMR (CDCl3) δ 173.3, 170.6, 159.2, 
151.7, 131.0, 130.5, 128.1, 125.9, 125.2, 114.1, 76.7, 66.2, 62.2, 60.9, 55.6, 54.8, 
50.4, 42.1, 41.1, 40.3, 36.7, 34.9, 34.7, 31.5, 28.4, 27.6, 25.0, 23.1, 22.7, 22.0; m/z 
547.3 [M+]; Anal. Calcd for C34H46N2O4: C, 74.69; H, 8.48; N, 5.12. Found: C, 
74.53; H, 8.50; N, 5.09.  
(-)-Phenylmenthyl (1R, 5R, 6S)-6-(Acetylamino)-3-(4-methoxybenzyl)-3-
azabicyclo[3.2.1]octane-6-carboxylate endo-123b. Mp 86 °C (CH2Cl2/iPr2O); 
[α]D25 = -3.5° (c 6.4, CHCl3); IR νmax 3400, 1730, 1657 cm-1; 1 H NMR (CDCl3) 
δ 7.42-7.05 (m, 6 H), 7.05-6.95 (m, 1 H), 6.88 (d, J = 8.8, 2 H), 5.42 (s, 1 H, exch.), 
4.78-4.66 (m, 1 H), 3.82 (s, 3 H), 3.55, 3.22 (AB system, J = 13.0, 2 H), 2.90-2.80 
(m, 1 H), 2.58-162 (m, 10 H), 1.57 (s, 3H), 1.58-0.70 (m, 7 H), 1.29 (s, 3 H), 1.15 (s, 
3 H), 0.84 (d, J = 6.2, 3 H); 13C NMR (CDCl3) δ 171.0, 169.4, 158.8, 152.3, 131.0, 
130.2, 128.1, 125.8, 125.2, 113.7, 77.3, 68.5 61.5, 58.1, 55.7, 55.4, 50.2, 41.1, 40.3, 
39.1, 37.1, 35.0, 34.6, 31.6, 28.3, 27.6, 25.4, 23.5, 23.1, 22.1; m/z 547.3 [M+]; Anal. 
Calcd for C34H46N2O4: C, 74.69; H, 8.48; N, 5.12. Found: C, 74.50; H, 8.51; N, 5.07.  
 
General Procedure for the Oxidative Deprotection of 122a/123a. To a solution of 
compound 122a/123a (346 mg, 1 mmol), in acetone/H2O (23 mL, 9 : 1) at 0 °C, 
(NH4)2Ce(NO3)6 (2.19 g, 4 mmol) was added in several portion in 1 h. The mixture 
was stirred at room temperature for 3 h and quenched with a saturated solution of 
NaHCO3 (pH 10). A solid was formed. Acetone was evaporated and the aqueous 
layer was filtered trough a celite pad. After elution with warm EtOH, the organic 
solution was concentrated under reduced pressure. The crude material was purified 
by column chromatography on silica gel (CH2Cl2/MeOH/NH4OH = 5 : 1 : 0.025). 
Compound 126/127 (exo-126a: 204 mg, 90%; endo-127a: 141 mg, 62%) was 
isolated after recrystallization. 
Methyl (1S*, 5S*, 6S*)-6-(Acetylamino)-3-azabicyclo[3.2.1]octane-6-carboxylate 
exo-126a. Mp 110 °C dec. (EtOH); IR νmax 3400, 1727, 1632 cm-1; 1H NMR (D2O) δ 
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3.58 (s, 3 H), 3.10 (brs, 4 H), 2.86 (brs, 1 H), 2.55 (dd, J = 15.4, 7.3, 1 H), 2.39 (brs, 
1 H), 2.11-1.98 (m, 1 H), 1.92 (s, 3 H), 1.83  (dd, J = 15.4, 3.0, 1 H), 1.71  (dd, J = 
12.5, 2.6, 1 H); 13C NMR (D2O) δ 176.5, 175.5, 65.0, 53.5, 49.2, 45.9, 39.2, 38.8, 
34.2, 32.0, 21.9; m/z 227.2 [M+]; Anal. Calcd for C11H18N2O3: C, 58.39; H, 8.02; N, 
12.38. Found: C, 58.21; H, 8.18; N, 12.22. 
Methyl (1R*, 5R*, 6S*)-6-(Acetylamino)-3-azabicyclo[3.2.1]octane-6-
carboxylate endo-127a. Mp 99 °C dec. (EtOH); IR νmax 3420, 1720, 1645 cm-1; 1H 
NMR (D2O) δ  3.66 (s, 3 H), 3.21 (d, J = 12.5, 1H), 3.18-3.00 (m, 3 H), 2.56 (d, J = 
15.7, 1 H), 2.47 (brs, 2 H), 2.21-2.00 (m, 2 H), 1.93 (s, 3 H), 1.75 (d, J = 12.5, 1 H); 
13C NMR (D2O) δ 175.1, 173.9, 66.9, 53.9, 49.6, 45.8, 42.3, 39.8, 34.4, 32.5, 21.7; 
m/z 227.1 [M+]; Anal. Calcd for C11H18N2O3: C, 58.39; H, 8.02; N, 12.38. Found: C, 
58.30; H, 8.20; N, 12.14. 
6-Acetylamino-3-(4-methoxybenzyl)-3-azabicyclo[3.2.1]octane-6-carboxylic Acid 
(±)-132/133. Operating in a sealed tube, compound 122a/123a (346 mg, 1 mmol) 
was dissolved in EtOH (95%, 5 mL) and KOH (112.2 mg, 2 mmol) was added. The 
solution was heated at 120 °C under stirring for 2h. The reaction mixture was treated 
with HCl (6 N, pH 7) and the solvent was removed. The crude material was filtered 
through a pad of silica gel with CH2Cl2/CH3OH (5 : 2). Crystallization from absolute 
EtOH afforded the pure carboxylic acid derivative 132/133 [(±)-exo-132: (315 mg, 
95%); (±)-endo-133: (330 mg, 99%)].  
(1S*, 5S*, 6S*)-(±)-exo-132: mp 200 °C (EtOH); IR νmax 3412, 1740, 1661 cm-1; 1H 
NMR (CD3OD) δ 7.61, 7.00  (AA'XX' system, J = 8.4, 4 H), 4.42, 4.01 (AB system, 
J = 11.0, 2 H), 3.83 (s, 3H), 3.56, 3.17 (AB system, J = 11.0, 2 H), 3.10-1.90 (brs, 2 
H), 2.81 (d, J = 12.2, 1 H), 2.63 (d, J = 14.2, 1 H), 2.50 (brs, 1 H), 2.41 (dd, J = 14.7, 
7.0, 1 H), 2.38-2.29 (m, 1 H), 1.92 (s, 3 H), 1.78 (d, J = 11.2, 1 H); 13C NMR 
(CD3OD) δ 176.9, 172.7, 160.2, 131.5, 120.9, 113.4, 65.0, 59.7, 57.6, 53.8, 53.0, 
40.0, 36.4, 33.9, 32.8, 20.9; m/z 333.2 [M+]; Anal. Calcd for C18H24N2O4: C, 65.04; 
H, 7.28; N, 8.43. Found: C, 65.12; H, 7.38; N, 8.50. 
(1R*, 5R*, 6S*)-(±)-endo-133: mp 202 °C dec. (EtOH); IR νmax 3435, 1613, 1516 
cm-1; 1H NMR (CD3OD) δ 7.42, 6.98 (AA'XX' system, J = 8.4, 4 H), 4.16, (brs, 2 H), 
3.80 (s, 3 H), 3.40-3.20 (m, 3 H), 3.11 (d, J = 12.1, 1 H), 2.66 (d, J = 15.0, 1 H), 2.53 
(brs, 2 H), 2.30-2.02 (m, 2 H), 1.92 (s, 3 H), 1.88 (d, J = 11.5, 1 H); 13C NMR 
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(CD3OD) δ 177.2, 170.9, 160.2, 131.1, 120.7, 113.6, 67.6, 58.7, 56.2, 54.4, 53.8, 
42.3, 41.2, 33.8, 33.6, 20.8; m/z 333.3 [M+]; Anal. Calcd for C18H24N2O4: C, 65.04; 
H, 7.28; N, 8.43. Found: : C, 65.00; H, 7.30; N, 8.39. 
General Procedure for the Hydrolysis of Amino Acid Function. i) Operating in a 
sealed tube, compounds (±)-exo-122a,123a or (±)-endo-122a,123a (1 mmol) were 
suspended in HCl (1 mL, 6 M) and the mixture was heated at 120 °C for 24 h. The 
solvent was removed and the crude amino acids (±)-exo-134a (mixture of conformers 
7 : 1), exo-135a and (±)-endo-134a,135a were isolated as bis-chlorhydrate in 
quantitative yield. ii) Operating in a sealed tube, MeOH (5 mL) was cooled at 0 °C 
and Na (161 mg, 7 mmol) was added. Compound 122b (546.7 mg, 1 mmol) was 
added and the mixture was heated at 100 °C under stirring for 50 h (TLC: 
CH2Cl2/MeOH, 50 : 1). The solvent was removed and the crude reaction mixture was 
taken up with distilled H2O (5 mL) and extracted with AcOEt (3 x 10 mL). The 
aqueous solution was treated with HCl (6N, pH 1) and was purified by a Dowex 50W 
x 4-50 ion exchange resin which was first activated with NH4OH (2N) then with 
AcOH (2 N, pH 4) followed by washing with H2O (pH 7). The reaction mixture was 
deposited on the resin which was rinsed with water. The amino acid was eluted with 
aqueous NH4OH (2 N). Ninhydrin positive fractions (T.L.C. 
CH2Cl2/MeOH/NH4OH(15%) = 5 :3 : 0.9) were pooled and evaporated to give (-)-
exo-134b’ (130 mg, 45 %) from (-)-exo-122b’ and (-)-endo-135b’ (172 mg, 60 %) 
from (-)-endo-123b’.  
6-Amino-3-(4-methoxybenzyl)-3-azabicyclo[3.2.1]octane-6-carboxylic Acids:  
(1S*, 5S*, 6S*)  (±)-exo-124a . 2 HCl: mixture of isomers (8 : 1). Mp 176 °C 
(acetone/H2O); IR νmax 3470-3370, 1742, 1614 cm-1; 1H NMR (D2O) δ major isomer: 
7.32, 6.92 (AA'BB' system, J = 8.8, 4 H), 4.29, 4.13 (AB system, J = 12.8, 2 H), 3.70 
(s, 3 H), 3.52, 3.37 (AB system, J = 14.3, 2 H), 3.15 (brs, 2 H), 2.70-2.55 (m, 2 H), 
2.52-2.48 (m, 1 H), 2.30-2.10 (m, 1 H), 1.62 (d, J = 4.0 1 H), 1.56 (d, J = 8.4, 1 H); 
minor isomer (significative signals): 7.18, 6.80 (AA'BB' system, J = 8.8, 4 H); 13C 
NMR (D2O) δ 173.1, 160.5, 133.3 (133.5), 120.3, 114.5 (115.9), 64.6, 61.9, 57.5, 
55.5, 52.5, 41.5, 33.8, 33.0, 32.5; m/z 291.8 [M+]; Anal. Calcd for C16H24Cl2N2O3: C, 
52.90; H, 6.66; N, 7.71. Found: C, 52.50; H, 7.00; N, 7.28.  
(1S, 5S, 6S)  (-)-exo-134b’: [α]D25 = -36.3° (c 3.7, MeOH).  
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(1R*, 5R*, 6S*) (±)-endo-135a . 2 HCl: mixture of isomerss (3 : 1).  Mp 220-221 °C 
(EtOH); IR νmax 3405-2950, 1725, 1614 cm-1; 1H NMR (D2O) δmajor isomer:  7.35, 
7.01 (AA'BB' system, J = 8.8, 4 H), 4.18, 4.12 (AB system, J = 13.1, 2 H), 3.79 (s, 3 
H), 3.44, 3.16 (AB system, J = 11.2, 2 H), 3.28-3.13 (m, 2 H), 2.71 (brs, 1 H), 2.66 
(brs, 1 H), 2.46 (dd, J = 15.7, 2.1, 1 H), 2.17 (dd system, J = 15.7, 7.2, 1 H), 2.09-
2.07 (m, 1 H), 1.94 (d, J = 13.5, 1 H); minor isomer (significative signals): 7.28, 6.90 
(AA'BB' system, J = 8.8, 4 H); 13C NMR (D2O) δ 174.6, 160.3, 132.4 (132.2), 121.3 
(120.6), 114.9 (116.2), 67.1, 59.96 (60.03), 56.99 (56.93), 55.5, 54.5, 42.8, 38.9, 
34.2, 33.9; m/z 291.8 [M+]; Anal. Calcd for C16H24Cl2N2O3: C, 52.90; H, 6.66; N, 
7.71. Found: C, 52.53; H, 7.69; N, 7.29.  
(1R, 5R, 6S) (-)-endo-135b’  [α]D25 = -14.0° (c 4.25, MeOH).  
(1S*, 5S*, 6S*) 6-Amino-3-azabicyclo[3.2.1]octane-6-carboxylic Acid 2 HCl (±)-
exo-130: IR νmax 3600-2950, 1695, 1626 cm-1; 1H NMR (2 . HCl salt D2O) δ 3.51 
(dd, J 14.6, 3.1, 1 H), 3.45 (dt, J 14.6, 2.2, 1 H), 3.37-3.24 (m, 2 H), 2.89 (dd, J 15.9, 
8.0, 1 H), 2.78 (brs, 1 H), 2.62 (brs, 1 H), 2.45-2.28 (m, 1 H), 1.85 (dd, J 15.9, 1.9, 1 
H), 1.79 (dd, J 13.0, 2.1, 1 H); 13C NMR δ 172.6, 63.1, 48.9, 42.9, 39.6, 33.6, 32.2, 
31.0; m/z 172.2 [M]+; Anal. Calcd for C8H16Cl2N2O2: C, 39.52; H, 6.63; N, 11.52. 
Found: C, 39.05; H, 6.96; N, 11.30. 
(1R*, 5R*, 6S*) 6-Amino-3-azabicyclo[3.2.1]octane-6-carboxylic Acid 2 HCl (±)-
endo-131. IR νmax 3600-2950, 1697, 1627 cm-1; 1H NMR (D2O) δ 3.35 (dt, J 12.7, 
2.4, 1 H), 3.27 (brs, 2 H), 3.23 (d, J 12.7, 1 H), 2.71 (brs, 1 H), 2.68 (brs, 1 H), 2.57 
(dd, J 15.9, 2.1, 1 H), 2.24 (dd, J 15.9, 7.4, 1 H), 2.20-2.12 (m, 1 H), 1.98 (dd, J 13.2, 
2.1, 1 H); 13C NMR (D2O) δ 173.2, 66.3, 48.4, 45.7, 41.4, 37.7, 33.2, 32.6; m/z 172.2 
[M]+; Anal. Calcd for C8H16Cl2N2O2: C, 39.52; H, 6.63; N, 11.52. Found: C, 39.01; 
H, 6.98; N, 11.28. 
General Procedure for the Reductive Amination from Aldehydes 120a, 121a: 
Synthesis of 3-aza-bicyclo[3.2.1]octane exo-124, 124’, 122c and endo-125, 125', 
123c. A mixture of aldehydes 120a, 121a (241 mg, 1 mmol) was dissolved in 
anhydrous dichloroethane (4 mL) under N2 and stirring at 25 °C. (R)-1-
Phenylethylamine (50 µL, 1.1 mmol) or MeNH2 (32.6 mg, 1.05 mmol), 
NaBH(OAc)3 (530 mg, 2.5 mmol) and AcOH (catalytic amount) were added. After 
36 h, the solvent was eliminated, the mixture was taken up with CH2Cl2 (5 mL), 
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washed with H2O (5 mL) and dryed over MgSO4. In the case of phenylethylamine 
(1.45 mL, 31.9 mmol) the reaction has been scaled up starting from aldehydes 120a, 
121a (7 g, 29 mmol) to give a mixture of diastereoisomers (7.6 g, 80%) which were 
chromatographed on silica gel (CH2Cl2/MeOH, 20 : 1), affording the mixture exo-
124/124' (5.3 g, 56%) and endo-125/125' (2.3 g, 24%). Using a Biotage 
chromatographic system (column: FLASH 65i, KP-SIL, 65x200 mm; exo-124/124': 
cyclohexane/AcOEt, 3:2; endo-125/125': CH2Cl2/MeOH, 10:1) pure (+)-exo-124 
(2.3 g, 25%) was separated from (-)-exo-124’ (2.65 g, 28%) and (+)-endo-125 (1.15 
g, 12%) from (-)-endo-125’ (0.95 g, 10%). Pure (±)-exo-122c (57 mg, 24%) and (±)-
endo-123c (21.6 mg, 11%) were isolated after column chromatography 
(CH2Cl2/MeOH, 50 : 1) and crystallization. 
General Procedure for the Deprotection of N-3. Compound (±)-exo-122a or (±)-
endo-123a (346 mg, 1 mmol) or (-)-exo-124’ or (+)-endo-125 (330 mg, 1 mmol) or (-
)-exo-132’ or (-)-endo-133 (290 mg, 1 mmol) was dissolved in MeOH (10 mL). Pd/C 
(10 %, 100 mg, 0.1 mmol) was added and the mixture was hydrogenated (25 °C, 1 
atm; exo-122a and endo-123a: 48 h; exo-124’ and endo-125: 36 h; exo-132’ and 
endo-133: 24 h). The catalyst was filtrated over a celite pad, the solvent was removed 
and the mixture was purified by column chromatography on silica gel 
(CH2Cl2/MeOH, 1 : 1). Pure compound [from (±)-exo-122a: (±)-exo-126a (165 mg, 
73%); from (±)-endo-123a: (±)-endo-127a (158 mg, 70%); from (-)-exo-124’: (-)-
exo-122f’ (192 mg, 85%); from (+)-endo-125: (+)-endo-122f (165 mg, 73 %), from 
(-)-exo-132’: (-)-exo-130 (142 mg, 84%); from (-)-endo-133: (+)-endo-131 (160 mg, 
95%)] was isolated after crystallization. Spectroscopic data of known compounds are 
in agreement with literature.2 
6-Amino-3-aza-bicyclo[3.2.1]octane-6-carboxylic Acids exo-130 and endo-131 . 
2 HCl. The hydrochloride salt was obtained after treating compounds (-)-exo-130 
and (+)-endo-131 with a solution of anhydrous HCl in EtOH. 
(-)-(1S, 5S, 6S)-exo-130 . 2 HCl: [α]D25 - 9.0 (c 0.5, MeOH).  
(+)-(1R, 5R, 6S)-endo-131 . 2 HCl: [α]D25 + 4.0 (c 0.5, MeOH). 
General Procedure for the “One Pot” Deprotection-Alkylation Reaction of N-
3. Compound (±)-exo-122a or (±)-endo-123a (150 mg, 0.432 mmol) or (+)-exo-124 
or
 
(-)-exo-124’ or (+)-endo-125 or (-)-endo-125’ (100 mg, 0.303 mmol) was 
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dissolved in the proper solvent (see below: 10 mL). A catalytic amount of AcOH and 
the carbonyl compound were added [for c: MeOH and formaldehyde (37 % MeOH 
solution, 200 µL, 1.2 mmol); for d: EtOH and acetaldehyde (25 µL, 0.476 mmol); for 
e: acetone and water 1:3]. The mixture was hydrogenated with Pd/C (10%, 47 mg, 
0.044 mmol) at 25 °C and 1 atm for 24 h. The catalyst was filter over celite, the 
solvent was eliminated  affording the expected compounds of c series  [from (±)-exo-
122a: (±)-exo-122c (90 mg, 88%); from (±)-endo-123a: (±)-endo-123c (88mg, 85%); 
from (+)-exo-124: (+)-exo-122c (50 mg, 70%); from (-)-exo-124’: (-)-exo-122c’ (58 
mg, 80%); from (+)-endo-123b: (+)-endo-123c (60 mg, 83%); from (-)-endo-123b’: 
(-)-endo-123c’ (62 mg, 85%)] or (±)-exo-122d (from (±)-exo-122a: 100 mg, 90%) or 
(±)-endo-123d (from (±)-endo-123a: 75 mg, 68 %) or (±)-exo-122e (from (±)-exo-
122a: 81 mg, 70%) after crystallization. 
Synthesis of Methyl (±)-(1S*, 5S*, 6S*)-6-Acetamido-3-(4,4-diphenylbut-3-
enyl)-3-aza-bicyclo[3.2.1]octane-6-carboxylate exo-122g. To a solution of (±)-exo-
126d (297 mg, 1.3 mmol) in DMF (20 mL), 4-bromo-1,1-diphenylbut-1-ene (565 
mg, 1.96 mmol), K2CO3 (370 mg, 2.68 mmol) and NaI (78 mg, 0.52 mmol) were 
added. The reaction was stirred at reflux for 48 h (TLC: CH2Cl2/n-hexane, 4:1). The 
reaction mixture was poured into water (10 mL) and extracted with Et2O (3 x 10 
mL). The organic layer was washed with a saturated solution of NaCl (3 x 10 mL), 
dried over Na2SO4. After flash column chromatography on silica gel (CH2Cl2/MeOH, 
40:1) pure compound (±)-exo-122g was obtained (170 mg, 30%).  
General Procedure for Hydrolysis of Amino Acid Function. Operating in a 
sealed tube, compound (+)-exo-122c or (-)-exo-122c’ or (+)-endo-123c or (-)-endo-
123c’ or (+)-exo-133 or (-)-exo-122f’ or (+)-endo-122f or (-)-endo-132’ or (±)-exo-
122d or (±)-exo-122g (1 mmol) was suspended in 6N HCl (1 mL) and the mixture 
was heated at 120 °C for 14 h. The solvent was removed and the corresponding acids 
exo-128, exo-128’, endo-129 and endo-129' , (+)-exo-137, (-)-exo-137, (+)-endo-138, 
(+)-endo-138’ were isolated in quantitative yield. Spectroscopic data of known 
compound are in agreement with literature.2 
(-)-(1S, 5S, 6S)-6-Amino-3-aza-bicyclo[3.2.1]octane-6-carboxylic Acid exo-130 . 
2 HCl: [α]D25 - 9.3 (c 0.5, MeOH).  
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(+)-(1R, 5R, 6S)-6-Amino-3-aza-bicyclo[3.2.1]octane-6-carboxylic Acid endo-
131 . 2 HCl [α]D25 + 4.9 (c 0.5, MeOH). 
 
General Procedure for the Fmoc protection. Compound (-)-.exo-137’(226 mg, 
0.65 mmol); was suspended in 1,4-Dioxane (10 mL). After addition of aqueous 
solution NaHCO3 (6mL) the pH turned basic. FmocOSu (240 mg, 0.914 mmol) was 
dissolved in 5 mL of Dioxane and dropped into the stirring solution. The reaction 
mixture was stirred (overnight, 25 °C). The solvent was evaporated. The crude 
reaction mixture was solubilized in HCl 2N (10 mL) to pH acid and the product was 
precipitated and filtered off.  Product (-)-.exo-140’ ( 332 mg, 0.67 mmol) 
 
(1S, 5S, 6S, 1’R) 6-Amino((9H-fluoren-9-yl)methylcarbamoil)-3-
azabicyclo[3.2.1]octane-6-carboxylic Acid (-)-exo-140’. [α]D25 = - 18.9° (c 0.3, 
MeOH); IR νmax  cm-1; 1H NMR (CD3OD) δ 1.56 (d, J  7.0, 3 H) 1.67 (brs, 2H)  1.8-
2.0 (brs 1 H), 2.32-2.54 (m, 2 H), 2.80 (s, 2 H), 3.09 (brs, 2 H), 3.87 (d, J 6.2, 1 H), 
4. 15 (d, J 3.3, 1 H), 4.21 (d, J 5.9, 1 H), 4.33 (d, J  7.0, 1 H), 4.47 (brs, 1 H), 4.65 (d, 
J 7.0, 2 H), 7.29-7.38 (m, 7 H), 7.6-7.83 (m, 6 H); 13C NMR (CD3OD) δ 175.2, 
157.8, 144.2, 144.0, 141.5, 134.6, 130.0, 129.4, 127.9, 127.4, 125.5, 125.2, 120.0, 
67.2, 67.1, 56.8, 52.0, 41.2, 34.7, 33.8, 30.0, 25.4, 14.5 m/z 497.2 [M]+; Anal. Calcd 
for C31H32N2O4: C, 74.98; H, 6.50; N, 5.64. Found: C, 75.01; H, 6.51; N, 5.63. 
 
General Procedure for the Boc protection of compounds 137 and 137’. 
Compounds (+)-.exo-137 (398,8 mg, 1.08 mmol) or (-)-.exo-137’(400 mg, 1.15 
mmol); was suspended in ButOH (10 mL). After addition of aqueous solution NaOH 
2N (6mL) the pH turned basic. Boc anhydride  (1,3 g, 6.3 mmol) was dissolved in 15 
mL of H2O and dropped into the stirring solution. The reaction mixture was stirred (3 
days, 25 °C). the solution was concentred and the Boc anhydride was extracted with 
diethylether. HCl 2N was added in the solution to pH = 4 and cooling the water 
solution and the product precipitate and was filtered of giving respectively (+)-.exo-
N (mg, mmol yield 40%)or (-)-.exo-N(mg, mmol yield 35%). 
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(1S, 5S, 6S, 1’R) 6-Amino((ter-Buthyl)carbamoil)-3-azabicyclo[3.2.1]octane-6-
carboxylic Acid (-)-exo-153’. [α]D25 = -57.97° (c 5.25, MeOH); IR νmax 3600-2950, 
1691, 1600, 1500, 1169 cm-1; 1H NMR (CD3OD) δ 1.3-1.4 ( m, 6 H), 1.44 (s, 9H) 
1.53- 1.61 (d,d, J 13.6, 2.2, 1 H), 1.93 (brs, 2H), 2.05-2.11(brs, 2H), 2.24 (d,d, J  
13.5, 6.6, 1 H) 2.49 (d, J 6.2, 1 H), 2.73 (s, 1H), 2.99 (d, J 7.0, 1 H), 3.20-3.29 (d,d, J  
1 H), 7.30-7.25 (m, 5 H); 13C NMR (CD3OD) δ 181.3, 156.9, 145.5, 128.2, 127.2, 
126.7, 78.5, 67.6, 65.3, 58.0, 53.3, 43.6, 40.5, 37.3, 34.4, 27.7, 20.4; m/z 375.2 [M]+, 
397.2 [M+Na+]; Anal. Calcd for C21H30N2O4: C, 67.35; H, 8.07; N, 7.48. Found: C, 
67.38; H, 8.08; N, 7.49. 
(1R, 5R, 6R, 1’R) 6-Amino((ter-Buthyl)carbamoil)-3-azabicyclo[3.2.1]octane-6-
carboxylic Acid (+)-exo-153. [α]D25 = +19.5° (c 5.36, MeOH);IR νmax 3600-2950, 
1691, 1600, 1500, 1169 cm-1; 1H NMR (CD3OD) δ 1.31-1.439 ( m, 6 H), 1.39 (s, 9H) 
1.61- 1.69 (d,d, J 13.6, 2.6, 1 H), 1.95 (d, J  9.3,  1H), 2.1 (brs, 2H), 2.18 (d, J 9.9, 
1H), 2.41 (d,d, J  14.0, 6.6, 1H), 2.50 (brs, 1H), 2.57 (d, J 11.0, 1H), 2.88 (d, J 9.5, 
1H), 3.32 (q, J 6.6,14.1, 1H) 7.25-7.35 (m, 5H);13C NMR (CD3OD) δ 181.4, 156.6, 
144.1, 128.2, 127.5, 126.6, 67.4, 65.2, 56.8, 53.7, 41.1, 37.1, 34.4, 27.7, 18.6; m/z 
375.2 [M]+, 397.2 [M+Na+]; Anal. Calcd for C21H30N2O4: C, 67.35; H, 8.07; N, 7.48. 
Found: C, 67.36; H, 8.06; N, 7.48. 
 
General Procedure for the synthesis of peptide 154, 155 via solid-phase peptide 
synthesis.  
Peptide 154, 155  were synthesized via solid-phase synthesis using manual coupling 
steps on a peptide rink amide linker MBHA (0.58 mmol/g) solid support. The resin 
was swelled for 30 minute in DMF, after which the Fmoc protecting group was 
cleavage with a DMF/Piperidine solution (1 mL 40% of piperidine, 3 minute).  We 
repeated the cleavage DMF/Piperidine solution (1 mL 20% of piperidine, 10 minute) 
and the resin was washed with DMF to remove all the Fmoc residue. 
Each oligomer was synthesized manually. Double coupling of the N-α-Fmoc natural 
amino acids was performed using a mixture of amino acid/HOBt/HBTU/DIPEA (4 
eq. each) in DMF for all  four  coupling. A single coupling of the Fmoc-ABO-OH (6 
eq.) using HBTU (8 eq.)/HOAt (8 eq.)/Collidine (10 eq.) in DMF for  4h was 
preferred. After each coupling, the not reacted amino acid coupled chain was stopped 
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using a acetylation reaction with acetic anhydride (17 µL in 0.5 mL of DMF) DIPEA 
for 30 minute. Fmoc cleavage  was developed using  DMF/Piperidine solution (1 mL 
40% of piperidine, 3 minute)  than we repeated the cleavage DMF/Piperidine 
solution (1 mL 20% of piperidine, 10 minute) and the resin was washed with DMF to 
remove all the Fmoc residues.  
 
General Procedure for the synthesis of peptide 156 via solution-phase peptide 
synthesis.  
 
Coupling reaction  
 
 (+)-exo-ABO 153’,159,162,164  ( 1 eq.)   was dissolved in  CH2Cl2( 10 mL) of. 
DIPEA ( eq.), HOBT ( 10 eq.),  EDC ( 10 eq.) and L-Ala-OMe ( 5 eq.) were added to 
the solution mixture and the reaction was stirred at 25°C for two days. The organic 
phase was washed with water and dried over Na2SO4. The solvent was removed and 
the crude product was purifided over SiO2 ( CH2Cl2 : Et2O). Giving pure compound 
N ( Yield 40%). 
 Boc deprotection  
 
Compound 158, 161, 163 was solubilized in a solution of TFA/CH2Cl2  and stirred 
overnight at 25°C. The solution was treated with a acqueous solution of Na2CO3 and 
the product was estracted with CH2CL2, dried and the solvent was removed under 
reduced pressure. The compounds were analyzed without further purifications. 
 
∆δNH/∆T 
We have prepared a sample dissolved compound 156 and 164 in CD3CN and a series 
of 1H spectra to different temperature have been registered. The analytical data of the 
δNH have been reported below (only the signals without overlapping were 
reported)in the table 10. 
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Table 10  tetrapeptide 164  
δNH4 7.13 7.11 7.08 7.06 
T°K 253 268.9 299.91 337 
δ NH2 7.88 7.86 7.82 7.78 
T°K 253 268.9 299.91 337 
a
 [peptide 164] = 14,8 mM in CD3CN, T° = 253 K to 337 K 
Table 11 pentapeptide 156a 
δNH5 7.87 7.84 7.80 7.66  7.54 7.50  
T°K 212.04 223.75 245.61 271.51 288.31 299.94 314.57 348.33 
δ NH4 
   7.66 7.57 7.51 7.46  
T°K 212.04 223.75 245.61 271.51 288.31 299.94 314.57 348.33 
δ NH3 7.70 7.66 7.61 7.57 7.52 7.50 7.47  
T°K 212.04 223.75 245.61 271.51 288.31 299.94 314.57 348.33 
δNH2 
       7.20 
T°K 212.04 223.75 245.61 271.51 288.31 299.94 314.57 348.33 
δ NH1 6.38 6.33  6.30 6.16 6.05 5.92 5.67 
T°K 212.04 223.75 245.61 271.51 288.31 299.94 314.57 348.33 
a
 [peptide 156] = 16,8 mM in CD3CN, T° = 212,04 K to 348.33 K 
Table 12 Kinetic Exchange data of the tetrapeptide 164  
[peptide 164] = 14,8 mM in CD3CN (700 µL) then D2O (20 µL), T = 299.94 K 
 
      NH4 = 7,08 NH2 = 7,82 
N° prova  N° exp. t (s)     
0 60 0 1,3 1,3 
1 61 280  exchanged 
2 62 310 0,65   
3 63 340 0,57   
4 64 370    
5 65 400 0,44   
6 66 430 0,4   
       
7 67 490    
8 68 550 0,3   
9 69 610 0,25   
10 70 670 0,19   
11 71 730    
12 72 790    
13 73 850 0,12   
14 74 910    
15 75 970 exchanged   
16 76 1030    
       
17 77 1330    
18 78 1630     
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Table 13 kinetic exchange data for the pentapeptide 156 with D2O: 
[peptide 156] = 16,8 mM in CD3CN (700 µL) then D2O (20 µL), T = 299.94 K 
 
N° N°exp  time NH1 NH2 NH3 NH4 NH5 
   s       
    7.55 7.52 7.47 7.42 6.03 
          excanged  overlapped   
0  0 1,08 1,08   1,8 
1 31 280 0,92 1,06   0,63 
2 32 310 0,91 1,04   0,52 
3 33 340 0,91 1,06   0,43 
4 34 370       
5 35 400 0,88 1,05   0,31 
6 36 430 0,85 1,05   0,26 
          
7 37 490 0,83 1,05     
8 38 550 0,8 1,04   0,18 
9 39 610       
10 40 670 0,77 1,03   0,12 
11 41 730       
12 42 790 0,75 1,03   0,07 
13 43 850       
14 44 910 0,71 1,01   0,05 
15 45 970       
16 46 1030 0,67 1,01   exchanged 
          
17 47 1330       
18 48 1630 0,6 1     
19 49 1930       
20 50 1530 0,6 1     
21 51 2130       
22 52 2730 0,49 0,95     
          
23 53 3930       
24 54 5130 0,42 0,95     
25 55 6330       
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26 56 8130 0,32 0,9     
27 57 9930       
28 58 11730 0,27 0,85     
29 59 13530 0,25 0,84     
          
30 60 17130 0,26 0,79     
31 61 20730 exchanged exchanged     
          
32 62 27930       
33 63 35130       
34 64 49530           
 
 
Metallorganic chemistry  
 
(S)-4-benzyl-4,5-dihydro-2-vinyloxazole 174: [α]D25 = -93.7° (c 10.2, CHCl3) IR 
νmax 3600-3000, 1666, 1645, 1454 cm-1; 1H NMR (CDCl3) δ 2.67 (AB system, J 
13.8, 8.4, 1 H), 3.15 (AB system, J 13.8, 5.5, 1 H), 4.04 (t, J 8.06, 1 H), 4.24 (t, J 
8.43, 1 H), 4.46 (m, J 8.4, 5.5, 1 H), 5.68(dd, J 10.6, 1.8, 1 H), 6.04 (dd, J 17.6, 1.8, 
1 H), 6.31 (dd, J 17.6, 10.6, 1 H), 7.19-7.35 (m, 5 H); 13C NMR δ 163.4, 129.4, 
128.8, 126.7, 126.2, 125.2, 71.7, 67.9, 41.9, 27.14; m/z 188.2 [M + H]+; Anal. Calcd 
for C12H13NO: C, 76.98; H, 7.00; N, 7.48. Found: C, 76.96; H, 6.98; N, 7.49. 
 
 
(endo)-(S)-4-benzyl-2-(bicyclo[2.2.1]hept-5-en-2-yl)-4,5-dihydrooxazole 175a: 
mixture of two diastereoisomers  IR νmax 3600-3200, 2971, 2930, 1660, 1453 cm-1; 
1H NMR (CDCl3) δ 0.80-0.85 (m, 1 H), 1.15-1.6 ( m, 9 H), 1.85-2.10 (m, 2 H), 2.4-
2.6 (m, 2 H), 2.8-3.2 (m, 10 H), 3.8-4.0 (m, 2 H), 4.0-4.2 (m, 2H), 4.2-4.4 (m, 2 H), 
5.8-6.0 (m, 2 H), 6.1-6.3 (m, 2 H), 7.1-7.4 (m, 10 H); 13C NMR δ 170.2, 138.2, 
137.63, 137.61, 132.68, 132.51, 129.6, 129.5, 129.57, 128.6, 126.5, 71.5, 71.45, 
67.27, 67.15, 49.8, 49.76, 46.03, 45.97, 42.77, 42.74, 41.9, 41.8, 37.5, 37.4, 30.4, 
30.3, 30.2, 29.9, 27.12 m/z 254.1 [M + H]+; Anal. Calcd for C17H19NO: C, 80.60; H, 
7.56; N, 5.53. Found: C, 80.58; H, 7.58; N, 5.55.  
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(endo)-(bicyclo[2.2.1]hept-5-en-2-yl)methanamine 165: compound known in 
licterature and prepared follow the procedure in the  L.I. Kasyan, I.N. Tarabara, O.A. 
Kasyan, O, Sergiy Tetrahedron, 2007, 63(8), 1790-1797 
 
(endo)-(bicyclo[2.2.1]hept-5-en-2-yl)-N-tosylmethanamine 166: mixture of two 
diastereoisomers; 1H NMR (CDCl3) δ 0.5 (m, 1 H), 1.1(d, 1 H), 1.4 (d, 1 H), 1.8 (m, 
1H), 2.2 (m, 1H), 2.45 (s, 3 H), 2.5-2.6 (m, 1H), 2.7-2.75 (m, 2 H), 2.8 (s, 1 H), 2.9 
(s, 1 H), 5.2 (bs, 1H), 5.75 (m, 1 H), 6.1 (m, 1H), 7.3(m, 2 H), 7.7 (m, 2 H). 
 
 
Organocatalysis  
 
General Procedure for the Diels-Alder reaction.  
Catalyst 128 (9 mg, 0.05 mmol) and cynnamaldehyde 182 (88 mg, 0.5 mmol) were 
solubilized in CH3CN/H2O solution (1.5 mL, 95:5), distilled cyclopentadiene ( 99 mg 
1.5 mmolo) was added into the solution. The reaction was stirred for 72 h or 42 h at 
25°C. The solvent was removed and the product were purified by column 
chromatography. The pure product mixture was analyze by chiral HPLC.  
 
General Procedure for Staudinger reaction  
 
Tioazolidinic acid 190 ( 50 mg, 0.214 mmol) was dissolved in toluene (5 mL), 
Mukayama activator 191 (63.4 mg, 0.247 mmol) and the protonsponge base 192 ( 
45.79 mg, 0.214 mmol) were added in the reaction mixture  and  warmed to 70°C for 
1h allow to obtain the relative chetene 193. Imid 194 ( 31.1 mg, 0.107 mmol) 
protonsponge base 192 (91.58 mg, 0.428 mmol) and catalytic base ABO 123a and 
125 (7,09 mg 0.0214 mmol) were dissolved in toluene ( 5mL) and dropped in the 
stirring reaction to 70° C or 25° C. The reaction was stirred overnight. The product 
mixture was then washed with HCl 2 N solution to remove the excess of base. The 
organic phase was dried over Na2SO4 and the product purified by column 
cromatography. 
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